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ABSTRACT 
Bipolar disorders (BD) are characterized by symptoms of grandiosity, decreased need for 
sleep, pressure to keep talking, flight of ideas, distractibility, increased goal-directed 
activities, psychomotor agitation, and excessive involvement in pleasurable activities.  
Those with a bipolar disorder have a high degree of psychiatric comorbidity including 
substance use disorders, and they also experience increased mortality.  Despite the 
widespread recognition of BD as an important psychiatric condition, available 
population-based estimates for BD prevalence differs across data sources.   
 
Cannabis is one of the most widely-used illicit substances.  Evidence supports it as a risk 
factor for psychotic symptoms and disorders.  Because populations with psychotic 
disorders and populations with bipolar disorder share genetic characteristics, cannabis 
may increase risk for bipolar disorders through the same pathways as it does with 
psychotic disorders.  Limited and conflicting evidence regarding the association of 
cannabis use and bipolar disorder is currently available.  This dissertation investigates 
cannabis use as a risk factor for incident manic symptoms and bipolar disorders in a large 
nationally representative longitudinal cohort.   
 
v 
The first aim of this dissertation is to evaluate the implications for manic, hypomanic and 
major depressive episode prevalence estimates arising from the different approaches to 
assessing DSM-IV criterion between two national surveys.  Differences in the assessment 
of impairment strongly influence manic or hypomanic classification within the NESARC.   
Compared to multiple imputation estimates (19.7% [95% CI: 19.3-20.1]) which treat 
depressed mood and anhedonia as separate symptoms, symptom assessment in the 
NESARC substantially underestimates major depressive episode prevalence (16.9% 
[95% CI: 16.1-17.6]). 
 
The second research objective examined self-reported cannabis use as a risk factor for 
incident manic symptoms, bipolar spectrum disorders (including manic and hypomanic 
episodes) and SCID-based recalibrated BD I and II.  Cannabis use risk was assessed in 
the population as a whole and in sub-populations defined by age, substance 
abuse/dependence status, and family history.  Among those reporting no lifetime major 
depressive or manic symptoms at baseline, self-reported past-year cannabis use was 
associated with increased odds of an incident week of extremely elevated or irritable 
mood accompanied by at least two manic episode criterion B symptoms (adj. OR 1.69, 
95% CI: 1.08-2.65, p=.02) over the three year follow-up period.  Among adults (ages 26 
to 45) >=1 reported use(s) of cannabis per week was associated with incident manic or 
hypomanic episodes (adjusted OR 2.52, 95% CI: 1.32-4.80, p=.006).  Among those 
endorsing no major depressive symptoms, substance abuse/dependence, or anti-social 
traits in their first degree relatives, past year cannabis use is associated with increased 
vi 
risk for incident bipolar spectrum disorders (adjusted OR 2.27, 95% CI: 1.01-5.10, p=.05) 
and CIDI recalibrated BD I and II (adjusted OR 5.49, 95% CI: 1.38-21.9, p=.02).  Past 
year cannabis use risk for DSM-IV manic or hypomanic episodes among those aged 26 to 
45 is concentrated in those with a baseline history of a substance use disorder (adj. OR 
2.00, 95% CI: 1.10-3.66, p=.02) as compared to those with no such history (adj. OR 1.87, 
95% CI: 0.49-7.21, p=.36).    
 
The third research objective of this dissertation was a sensitivity analysis using 
externally-predicted categorized exposures and continuous cannabis use propensities.  
The sensitivity analysis found evidence of exposure misclassification.  Exposures defined 
by external propensity scores had improved cross-sectional association with bipolar 
spectrum disorders compared to reported use when both were compared to an external 
standard.   No significant risk estimates were found for categorized predicted cannabis 
use among groups that were previously found to have significant risk from reported 
exposure.  However, among adults 18 to 45 years of age with no manic or major 
depressive symptoms at baseline, past year cannabis use propensity (as a log transformed 
continuous measure) was associated with incident manic or hypomanic episodes (adj. OR 
1.49, 95% CI: 1.10-2.03, p=.01).  Elevated risk for high cannabis use propensity (>=1 
use/week in the past year) was also found in this same group (adj. OR 1.33, 95% CI: 
1.03-1.72, p=.03).  Among those with no reported history of depression, substance 
abuse/dependence, or anti-social traits among their first-degree relatives, propensity for 
past year cannabis use (adj. OR 1.61, 95% CI: 1.11-2.32, p=.01) and propensity for >=1 
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use/week of cannabis in the past year (adj. OR 1.38, 95% CI: 1.03-1.85, p=.03) were 
associated with incident manic or hypomanic episodes.  Among those without a 
substance use history at baseline, propensity for past year cannabis use (adj. OR 1.63, 
95% CI: 1.33-1.55, p<.001) and propensity for >=1 use/week of cannabis in the past year 
(adj. OR 1.54, 95% CI: 1.26-1.88, p<.001) were associated with incident manic or 
hypomanic episodes.  Among those with a substance use history at baseline, propensity 
for past year cannabis use (adj. OR 1.26, 95% CI: 1.03-1.56, p= .03) was associated with 
incident manic or hypomanic episodes.  
 
The findings of the first aim support the conclusion that the AUDADIS substantially 
under-estimated lifetime major depressive episode prevalence compared to an imputed 
estimate that treated anhedonia and depressed mood as separate and concurrent MDE 
symptoms.  The operationalization of impairment for manic disorders in both the 
AUDADIS and CIDI strongly influences case identification, with the CIDI having 
suppressed manic and hypomanic prevalence estimates.  Evidence was found supporting 
the conclusion that self-reported cannabis use is a significant risk factor for incident 
bipolar spectrum outcomes within subpopulations in a nationally representative cohort.  
A sensitivity analysis finds evidence that supports the conclusion that increasing cannabis 
use propensity is associated with increased risk of bipolar spectrum outcomes within 
population subgroups, with the greatest increased risk among those with the lowest innate 
risk.  Under-reporting of illicit substance use is a major limitation in this dissertation; 
further study is needed with improved exposure measures. 
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Chapter I Introduction 
I A. Objective 
The objective of this dissertation research is to explore cannabis use as a risk factor for 
bipolar disorder (BD) among a nationally-representative sample of U.S. adults.  The 
National Comorbidity Survey Replication (NCS-R) and Epidemiological Catchment Area 
(ECA) studies found substantial role impairment among those who meet criteria for 
disorders across the bipolar disorder spectrum including those with sub-threshold BD.1, 2  
Evidence from a related disease state, psychosis, suggests that cannabis exposure may 
account for 8-50% of incident or recurrent disease episodes.3-5  However, limited and 
conflicting evidence exists for cannabis use as a risk factor for bipolar disorder.6-9  Only 
one prospective cohort study has addressed the association between cannabis and BD.7  
This study found a significant association [OR 4.98 (95% CI: 1.80–13.81)].  The BD 
onset definition used in this study may have resulted in prevalent cases being included at 
baseline.  However, this result is consistent with two prospective cohort studies which 
found cannabis as a risk factor for manic symptoms.6, 9  These results on the other hand 
conflict with a population-wide retrospective cohort study which found a null association 
[OR 1.13 (95% CI: 0.82 to 1.57)] between cannabis use by age 18 and future affective 
psychosis hospitalization (predominately BD diagnoses).8, 10  These divergent results 
point to a clear need to assess cannabis use (CU) as a risk factors for both BD and sub-
threshold BD (manic symptoms, hypomanic episodes) in a large epidemiological sample. 
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I B. Background: 
Bipolar disorders are characterized by symptoms of grandiosity, decreased need for sleep, 
pressure to keep talking, flight of ideas, distractibility, increased  goal-directed activity, 
psychomotor agitation, and excessive involvement in pleasurable activities.11  A 
diagnosis of Bipolar I is made if one or more manic episodes have occurred.  A manic 
episode is a distinct period of abnormally and persistently elevated, expansive, or irritable 
mood, lasting at least 1 week, that includes three or more of the seven previously 
mentioned symptoms (four or more if the mood is only irritable) and is characterized by 
marked impairment in social functioning.   A diagnosis of Bipolar II is made if both a 
Major Depressive Episode and a hypomanic episode have occurred but there is no history 
of BD-I, a manic episode, or psychosis.   Hypomanic episodes share the same symptom 
criteria as manic episodes but are distinct from manic episodes in that they can last for as 
little as 4 days, do not have psychotic or delusional symptoms, and while they represent 
an unequivocal change in functioning that is uncharacteristic of the person when not 
symptomatic, they are not severe enough to cause marked social impairment.  Population 
based estimates of the prevalence of bipolar disorder (I and II) range from about 1-6%.1, 2, 
12-17  There is evidence of substantial role impairment in those with bipolar disorder even 
when the patient is euthymic. 1, 2, 15, 18  Those with bipolar disorder have a high degree of 
psychiatric comorbidity including substance use disorders and also experience increased 
mortality.1, 15   
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Available nationally representative, population-based estimates for BD prevalence in the 
US differ across data sources.  The prevalence estimates for bipolar disorders, which are 
hierarchical with major depressive disorder, differ between the National Epidemiologic 
Survey on Alcohol and Related Conditions (NESARC) (4.4%; 95% CI: 4.3-4.6)  and the 
National Comorbidity Survey-Replication (NCS-R) ( 3.9%; 95% CI: 3.4-4.4, un-
recalibrated;17 and 2.1%; 95% CI: 1.7-2.4, recalibrated),1  the other large, US population 
representative study of psychiatric disorders. Similarly, the prevalence of major 
depressive disorder in NESARC was 13.2% (95% CI: 13.0-13.4), compared to 
significantly higher rates of 16.6% (95% CI: 15.6-17.6)17 or 16.9% (95% CI 15.8-17.9, 
after re-calibration of bipolar disorders) in the NCS-R.19-21  It is important to understand 
and address differences in the reported prevalence estimates for mania, hypomania and 
MDE between the NESARC and the NCS-R in order to make more meaningful and valid 
risk estimates. 
 
These differences are likely due in part to differences in the assessment approaches used.  
There are concerns regarding how best to assess BD prevalence specifically and mood 
disorders generally in population samples.  Evidence from major epidemiological studies 
points to an inadequacy in the differentiation between diagnosis and treatment need.22  
This concern has lead to methods to re-adjust population based samples to improve 
concordance with clinical re-assessment samples through adjustments in impairment or 
disability measures, symptom threshold, and duration criteria.1, 20, 22 
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I C. Study Population: the National Epidemiologic Survey on Alcohol and Related 
Conditions (NESARC) 
This dissertation will use National Epidemiologic Survey on Alcohol and Related 
Conditions (NESARC) survey data from both wave 1 (n= 43,093, response rate 81.2%)23, 
24and wave 2 (n= 34,653, cumulative response rate 70.2%).25  The NESARC is a 
nationally representative sample of those over 18 years of age who were interviewed in a 
face-to-face household setting. The sample represents the adult, non-institutionalized, 
civilian population of the United States, including the District of Columbia and all 50 
States. Residents in non-institutionalized, group-quarters housing, such as boarding 
houses, dormitories and shelters, were also included as well as military personnel living 
off base.26  The NESARC is the largest nationally representative longitudinal survey to 
date that has assessed substance use and substance use disorders, mood disorders and 
anxiety disorders as well as family history of depression, alcohol or drug abuse, and anti-
social behavior.       
I C. 1 Alcohol Use Disorder and Associated Disabilities Interview Schedule 
(AUDADIS) 
The NESARC represents an opportunity for researchers to better understand the impact 
of BD at the population level as well as risk factors for this condition, including cannabis 
use. However, a need exists to first accurately define and estimate the burden of BD in 
this survey.  The NESARC used the National Institute on Alcohol Abuse and 
Alcoholism’s (NIAAA) internally developed Alcohol Use Disorder and Associated 
Disabilities Interview Schedule (AUDADIS).27, 28  The AUDADIS is a structured 
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diagnostic interview designed for use by lay interviewers to generate diagnoses meeting 
DSM-IV criteria for alcohol and substance abuse and dependence as well as Axis I and 
Axis II disorders.  The Axis I and Axis II disorders assessed by the AUDADIS included 
mood disorders (major depressive disorder, dysthymia, mania and hypomania), anxiety 
disorders (generalized anxiety, panic, social phobia and specific phobia) as well as seven 
personality disorders (paranoid, schizoid, avoidant, dependent, obsessive–compulsive, 
histrionic, and antisocial disorders).  In wave 2 interviews, post traumatic stress disorder 
(PTSD) and childhood attention deficient hyperactive disorder (ADHD) were also 
assessed. The reliability of AUDADIS for alcohol and drug use disorder measures has 
been assessed in several test–retest studies in clinical and general population samples 
with good to excellent reliability for dependence but only fair to poor reliability for abuse 
diagnoses.27, 29-32  The test-retest reliabilities of the mood and anxiety disorder sections 
were fair to good.23, 29  Of the diagnoses of interest in this study only major depression 
was assessed in comparison with clinical diagnoses with good concordance (k=0.73).29  
No reliability or validity testing of the diagnosis outcomes of the High Mood section 
(mania/hypomania) of the AUDADIS are available, though dimensional symptom scales 
demonstrated fair reliability (k=0.60 (95% CI: 0.53- 0.64).23 
 
I C. 2 AUDADIS and clinical significance 
 The issue of clinical significance arises in the High Mood section of the AUDADIS used 
in the NESARC to assess cases of mania and hypomania.  A reasonable interpretation of 
how the AUDADIS operationalized the social functioning requirements of DSM-IV 
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mania criterion D may mean that up to 30% of those classified with mania in the study do 
not meet DSM- IV criterion D levels of social functioning impairment.  A second 
potential source of discrepancy that has drawn less attention than the assessment of 
functional impairment is the operationalization of the symptom criteria in instruments 
used in major population based epidemiological surveys such as the NESARC.  
Preliminary evidence points to limitations in how major depressive symptoms were 
operationalized in AUDADIS, the diagnostic instrument of the NESARC.  Large, well-
executed, publicly-funded, population-based studies of psychiatric disorders play a 
critical role in providing service use and epidemiological evidence for researchers, 
clinicians and policy makers.  The importance of these studies will only increase as 
genetic material is sampled from population representative samples.33   
 
Two major methodological differences between the NESARC and the NCS-R likely 
account for most of the difference in prevalence estimates observed.  One difference is 
that the two surveys applied DSM-IV criteria differently in assessing mania, hypomania 
and major depressive episodes.  The other major difference is that the NCS-R reported re-
calibrated BD estimates based on a clinical re-assessment.1, 20 Briefly, the clinical re-
assessment used the Structured Clinical Interview for DSM-IV (SCID) 34 on a sub-set of 
those with manic symptoms and from this sample overall BD estimates were made.  As 
previously discussed,  the AUDADIS instrument used in the NESARC applies DSM-IV 
mania criterion D social impairment in a manner that likely results in misclassification of 
respondent as manic who more appropriately should be identified as hypomanic.  The 
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AUDADIS also does not operationalize elevated-mood-related hospitalization in those 
otherwise classified as hypomanic as grounds for re-classification as mania per DSM-IV 
criteria and as is done in the Composite International Diagnostic Interview (CIDI) 35, 36 
the diagnostic instrument used in the NCS-R.  A comparison of how the two surveys 
assessed depressive symptoms may help to account for differences in MDE and BD-II 
case identification.  DSM-IV major depression criterion A requires five (5) or more of 
nine (9) symptoms to have been present during the same 2-week period and at least one 
of the symptoms is either 1) depressed mood or 2) loss of interest or pleasure 
(anhedonia).11    The NCS-R explicitly assessed depressed mood, anhedonia and the 
remaining seven symptom states for the same episode and requires a total of five of nine 
symptoms to meet criterion A.37  The NESARC asked about lifetime depressed mood and 
lifetime anhedonia as stem questions for the remaining seven symptom states and further 
requires four of these seven symptoms to be endorsed for criterion A to be met.28    
 
The approach used in the NESARC results in depressed mood and anhedonia being 
treated as a single symptom state and as such, not being independently assessed within 
the same episode.  This approach is not a problem for those who endorse only depressed 
mood or anhedonia as their endorsement of four or more of the remaining symptoms will 
be consistent with DSM-IV criterion A.  For those endorsing both lifetime depressed 
mood and lifetime anhedonia a conflict with criterion A arises.  Respondents to the 
NESARC major depression symptom module who endorse both lifetime depressed mood 
and anhedonia and only three other symptoms of the remaining seven, though having 
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endorsed five symptoms, are skipped out of the major depression module and not further 
assessed.  As for the stem questions asked about lifetime symptoms of depressed mood 
and anhedonia, uncertainty exists as to whether these symptoms occurred in the same 
episode. This uncertainty of concurrency is the AUDADIS’s developers rationale for 
requiring the endorsement of at least four of the remaining seven symptoms.38  It is 
reasonable to suspect that a large proportion of the group endorsing both lifetime 
depressed mood and lifetime anhedonia and three other symptoms were referring to a 
concurrent presentation of depressed mood and anhedonia and would have met full 
criteria for major depression had these symptoms been assessed independently and these 
respondents were further assessed in the instrument for clinical significance and other 
criteria.  Preliminary results by the author find 2.2 % (95% CI: 2.1-2.3, n=943) of the 
entire NESARC sample endorsed both depressed mood and anhedonia and only three 
other major depressive symptoms.  This represents 9.8% (95% CI: 9.5-10.2) of all those 
endorsing five or more major depression symptoms (n=9760).  A need exists to re-
examine this group structurally overlooked by the AUDADIS.  Examining the proportion 
of respondents meeting full criteria for a major depressive episode among those 
endorsing both depressed mood and anhedonia and endorsing an additional 4 to 7 
symptoms and extrapolating this trend to 3 additional symptom endorsements (the un-
assessed group), an estimated 75% (R2 = 0.998) would have been classified as having a 
major depressive episode (MDE).  This corresponds to an estimated 18.2% prevalence of 
MDE compared with an un-readjusted prevalence of 16.5% (95% CI: 16.3-16.8).  This 
estimated readjustment shifts the NESARC MDE prevalence estimate closer to the NCS-
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R estimate of 19.2% (95% CI: 18.2-20.2).  About 8% of those in the ‘un-assessed’ MDE 
group who currently have hypomania without BD-II could be subject to reclassification 
as having BD-II (hypomania + MDE).  An examination of how MDE among the 
structurally overlooked group impacts BD-II and sub-threshold BD case identification 
after the application of the re-calibration algorithm will be carried out. 
 
I D. Cannabis use, psychosis and bipolar disorder 
Longitudinal population based studies point to cannabis as a risk factor for psychosis.39  
Cannabis use is suspected of playing a role in psychosis through dopamine 
dysregulation.40  Cannabis exposure may put carriers of the COMT Val(158)Met Val 
allele at a greater risk of psychosis.41, 42  The clinical presentation of BD often has similar 
features to the clinical presentation of schizophrenia.  Patients with BD often have 
psychotic symptoms and those with schizophrenic disorders often experience mania.43  
The two disorders may thus have a shared etiology.  Twin studies have found genetic 
correlations between schizophrenia and BD.44  Recently, the International Schizophrenia 
Consortium conducted a large, genome-wide association study and found evidence for a 
shared polygenic component to the risk of schizophrenia and BD.45  Thus, cannabis use 
may similarly be a risk factor for BD as it is for psychotic disorders. 
 
However, the limited evidence assessing cannabis use as a risk factor for bipolar disorder 
(BD) provides conflicting results.6-9  The one prospective cohort study to address the 
association between cannabis and BD,7 found a significant association [OR 4.98 (95% 
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CI: 1.80–13.81)] but the onset of BD was set at when the last symptom criteria were met 
rather than at the onset of the first affective episode.  This BD onset definition risks 
misclassifying prevalent BD at baseline which may inflate risk estimates.  The results of 
van Laar et al,7 are consistent with two prospective cohort studies, one using the same 
cohort,6.  Both find associations between manic symptoms and cannabis use: the 
Netherlands Mental Health Survey and Incidence (NEMESIS) OR 2.70 (95% CI: 1.54–
4.75)6 and the Early Developmental Stages of Psychopathology study (EDSP), OR 4.26 
(95% CI: 1.42–12.76)9 The manic outcome in the Henquet et al NEMESIS study may 
have had too low a symptom threshold, with respondents needing to only endorse one 
symptom persisting for 2 days (their operationalization of DSM-III-R criteria) to be 
positive for mania.  The EDSP study had a small sample size with only six cannabis 
exposed cases, raising questions of the power of their four leveled ordered logistic 
regression model to detect valid differences.  The results from the NEMESIS and EDSP 
studies conflict with the Swedish Conscript cohort, a population-wide retrospective study 
(n=50,087)  which found a null association [OR 1.13 (95% CI: 0.82 to 1.57)] between 
cannabis use by age 18 and future affective psychosis hospitalization (predominately BD 
diagnoses).8, 10  The examination of cannabis as a risk factor for manic symptoms and 
bipolar spectrum disorders in a large prospective epidemiological sample would 
contribute important evidence to the field. 
 
 
11 
I D.1 Cannabis Use and Bipolar Disorder: Substance Use Disorders and Family 
History 
In schizophrenia, cannabis abuse has been associated with earlier onset of the disorder.46, 
47  In BD, a substance use disorder has been hypothesized to be an added insult that may 
manifest in a later BD.48, 49  Evidence from a first admission mania cohort finds that those 
with a pre-existing cannabis use disorders (CUD) had a significantly later age-at-onset of 
mania as compared to those without a CUD or those experiencing a CUD after the onset 
of BD [No CUD: age (SD) 18 (10), BD<= CUD: 16 (6), CUD < BD: 23 (6), p = .002)].48  
Whether this result is merely the coincidence of the fact that the majority of CUD onset 
in the US population occurs by age 2050 needs to be examined further with a longitudinal 
epidemiological sample such as the NESARC.  One such approach is to investigate 
whether cannabis use status imparts different risk among those with histories of substance 
abuse/dependence and those without such histories, and to examine whether this risk is 
different for those at different developmental stages (ages 18-25 and those 26-45). 
 
Alcohol and substance abuse are highly comorbid with BD51  and alcohol abuse and BD 
aggregate in families.52  A family history of alcohol or substance abuse, depression, or 
anti-social behavior may be indicative of underlying risk for BD.53  Consequently, there 
exists a need to investigate whether cannabis use confers a greater risk for BD outcomes 
in individuals with alcohol or substance abuse histories as well as in those with family 
histories of depression, substance abuse and anti-social behavior.   
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I E. Bipolar Disorder Prevalence Estimates 
To adequately investigate the relationship of cannabis use to BD using NESARC data it 
is necessary to understand differences in the reported prevalence estimates for mania, 
hypomania and major depressive episodes (MDE) between the NESARC and the NCS-R.  
The lifetime prevalence of BD-I (DSM-IV)11 in NESARC wave 1 was 3.3% (95% CI: 
3.2-3.4) and BD-II at 1.12% (95% CI: 1.05-1.18) with the NCS-R reporting prevalence 
estimates of BD-I and II twice, one estimate before a clinical recalibration algorithm was 
applied and one after its application.   The NCS-R reported the lifetime prevalence of 
BD-I and BD-II as a group at 3.9% (95% CI: 3.4-4.4, un-recalibrated)17 and reported BD-
I at 1.0% (95% CI: 0.7-1.3, recalibrated), BD-II at 1.1% (95% CI: 0.9-1.3, recalibrated) 
and a sub-threshold bipolar group at 2.4%.1  The clinical re-calibration used in the NCS-
R reduced the prevalence estimates for BD-I and BD-II by nearly a half.  The prevalence 
of major depressive disorder (MDD) in NESARC was 13.2% (95% CI: 13.0-13.4), this 
compared to MDD of 16.6% (95% CI: 15.6-17.6)17 or 16.9% (95% CI 15.8-17.9, after re-
calibration of bipolar disorders)19-21 as seem in the NCS-R.  The large differences in 
prevalence reported between these two nationally representative epidemiological samples 
point to differing methodological approaches, approaches that need to be understood and 
addressed.  The difference in prevalence of MDD is explained in part by a higher rate of 
reported BD-I, BD-II and hypomania in the NESARC and possibly by differing 
methodological approaches by the two surveys in assessing DSM-IV mania, hypomania 
and MDE criteria.  A comparison of how the two surveys assessed mania, hypomania and 
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MDE will aid future research on bipolar spectrum disorders using the NESARC dataset 
by improving the validity of case identification.  This comparison is made in Chapter II. 
 
I F. Cannabis use reporting and the NESARC 
The exposure on which this dissertation focuses is self-reported cannabis use.  Cannabis 
is a controlled substance under federal and state laws.  Other researchers54 examining the 
NESARC have found relatively low prevalence estimates for the reported use of illicit 
substances including cannabis.  This may be due to features unique to the NESARC:  
specifically that the data was collected in face-to-face interviews by census workers 
(federal employees), rather than non-government contract researchers.  This may have 
suppressed reports of cannabis use.54  A goal of this dissertation is to assess whether 
cannabis use risk estimates differ if cannabis exposure classification conforms more 
closely with a less biased external exposure standard.  In short, cannabis use propensities 
will be modeled using NCS-R effect estimates within the NESARC and from these 
propensities a categorized predicted cannabis use measure will be defined.  Risk for 
bipolar outcomes associated with predicted cannabis use will be compared to reported 
cannabis use.  The cannabis use propensities, as continuous measures, will also be 
assessed as risk factors for bipolar spectrum outcomes. 
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I G. Research Aims 
As discussed, bipolar disorder is a serious psychiatric disorder.  Cannabis may be a risk 
factor for bipolar disorder.  The use of the NESARC represents an opportunity to 
examine cannabis use as a risk factor for bipolar disorder in a large longitudinal 
representative cohort and within potentially at-risk sub-populations.  To these ends the 
specific aims of this investigation are: 
Aim 1:  
1) Evaluate implications for mania, hypomania and MDE prevalence estimates 
arising from the different approaches to assessing DSM-IV criterion between the 
Alcohol Use Disorder and Associated Disabilities Interview Schedule 
(AUDADIS)28 used in the NESARC compared with the Composite International 
Diagnostic Interview (CIDI)35, 36 used in the NCS-R.   
a. Identify approaches for reconciling criterion implementation differences 
between the two surveys with the goal of aligning the AUDADIS 
implementation more closely with the CIDI implementation.   
b. Apply a clinically validated re-calibration algorithm used in the NCS-R19-
21 to the NESARC dataset to more accurately identify cases of BD-I, BD-
II and sub-threshold BD. 
c. Conduct an imputation analysis to assess the impact of missing 
data/criterion information on prevalence estimates for major depressive 
episode and bipolar spectrum disorders. 
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Aim 2:  
2) Examine cannabis use as a risk factor for incident (between NESARC wave 1 and 
wave 2) manic symptoms, bipolar spectrum disorders (DSM-IV11 manic and 
hypomanic episodes) and CIDI recalibrated BD I and II as defined by approaches 
used in Aim 1: 
a.  In the total population and within strata of young adults (ages 18-25) and 
adults (ages 25-45) with and without histories alcohol or drug 
abuse/dependence.   
b. Within strata defined by family history of depression, substance abuse or 
dependence and/or anti-social traits. 
c. Examine cannabis use risk for BD outcomes among those reporting and 
those not reporting any lifetime depressive or manic symptoms at baseline. 
Aim 3: 
3) A sensitivity analysis will be conducted using external information from the NCS-
R to produce propensity score models of cannabis use within the NESARC.  
Cannabis use propensity risk for incident bipolar outcomes will be assessed. 
a. Categorized predicted exposure risk estimates will be compared to 
reported exposure estimates.   
b. Cannabis use propensities will be assessed as risk factors for incident 
manic or hypomanic episodes in the population as a whole and among 
adults aged 18 to 45 
16 
c.  Risk will also be assessed within strata defined by family history and 
strata defined by substance use disorder history. 
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Chapter II Case Identification:  NESARC/NCS-R Comparison, Reconciliation, 
Recalibration and Missing Criterion Information Assessment: 
II A. Introduction 
 
The specific aims of the research reported in this chapter include evaluating the 
implications for lifetime mania (BD-I), hypomania, bipolar-II (BD-II) and MDE 
prevalence estimates arising from the differences in approach to assessing DSM-IV 
criterion between the Alcohol Use Disorder and Associated Disabilities Interview 
Schedule (AUDADIS)28 used in the National Epidemiologic Survey on Alcohol and 
Related Conditions (NESARC) and the Composite International Diagnostic Interview 
(CIDI) 35, 36 used in the National Comorbidity Survey Replication (NCS-R).  Approaches 
for reconciling criterion implementation differences between the two surveys will be 
identified.  The goal is to align the AUDADIS implementation of DSM-IV criteria to 
more closely adhere to the CIDI implementation.  After reconciling the two surveys 
criterion approaches, a clinically validated re-calibration algorithm used in the NCS-R19-
21 will be applied to the NESARC dataset.  The net result of this approach is to more 
accurately identify cases of BD I and BD II that rise to the level of treatment need.  
Lastly multiple imputation by chained equations (MICE)55 will be applied to both surveys 
with the objective of assessing the impact of missing criterion information on BD-I, BD-
II and sub-threshold BD prevalence estimates in the two surveys. 
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II B. The Surveys: 
II B. 1 The National Epidemiologic Survey on Alcohol and Related Conditions 
(NESARC): 
The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) was 
a three year longitudinal survey which fielded its first wave in 2001-2002 and the second 
wave in 2004-2005 assessing the same respondents.56 The National Institute on Alcohol 
Abuse and Alcoholism (NIAAA), part of the National Institutes of Health sponsored the 
study and the U.S. Bureau of the Census carried out the field work using computer 
assisted personal interviewing (CAPI).  The NESARC’s main focus, as the survey’s name 
implies, is alcohol use disorders and their related disabilities.  The NESARC is a 
nationally representative sample of those 18 years of age or older who were interviewed 
in a household setting. The sample represents the adult non-institutionalized civilian 
population of the United States, including the District of Columbia and all 50 States. 
Residents in non-institutionalized group quarters housing, such as boarding houses, 
dormitories and shelters were also included as well as military personnel living off base.26  
The NESARC is the largest epidemiological survey in the US to date to have assessed 
substance use and substance use disorders, mood disorders and anxiety disorders as well 
as family history of depression, alcohol or drug abuse, and anti-social behavior. 
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The NESARC sampling frame for housing units (HUs) comes from a Bureau of the 
Census national survey called the Census 2000/2001 Supplementary Survey (C2SS) 
which was conducted between 2000 and 2001 and included approximately 78,300 
households on a monthly basis.56   Also included in the NESARC was a group quarters 
(GQ) frame. The group quarters sampling frame comes from the Census 2000 Group 
Quarters Inventory.  The primary sampling units (PSUs) used in the NESARC mostly 
corresponds to the county-based PSUs found in the Census Bureau’s Current Population 
Survey (CPS) with differences accounted for by changes in county definitions and 
Metropolitan Statistical Areas (MSA).  The NESARC included samples from all of the 
PSU used in the C2SS but in order to maintain respondent confidentiality some PSUs 
were collapsed resulting in 435 PSUs.  
 
The second stage of sampling for the NESARC consisted of within-PSU selection.  The 
Census Bureau’s Master Address File (MAF) was the primary source of the C2SS 
sample.56  Information on race and ethnicity was collected as part of the C2SS and this 
was used to stratify housing units into three groups: Hispanic, non-Hispanic Black, and 
Other (non-Black, non-Hispanics).  Hispanic, non-Hispanic Black HUs were then over-
sampled.  This over-sampling was done to improve the reliability of statistical analysis 
among each of these major race/ethnic subgroups within United States population. A HU 
equivalence was assigned to Group quarters units and these were then sampled together 
with the other HUs.  Sampled HU or GQ entered the third stage of the NESARC 
sampling design. 
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Within each household selected in stage two a single individual was randomly selected 
from a list of persons residing in the household.56  In GQs the census interviewers 
obtained a list of those residing at the location and interviewed persons based on their 
position on that list.  Within households where young adults aged 18 to 24 years resided 
those 18 to 24 year olds were sampled at 2.25 times the rate of other household members.  
NESARC investigators over-sampled young adults in order to better assess adverse 
alcohol related outcomes in this population with an eye toward developing primary and 
secondary interventions. 
 
The NESARC wave 1 sample has been weighted to be representative of the non-
institutionalized adult (18 years of age and older) US population.  The weighting of the 
NESARC sample is the product of seven individual weights. 56    These individual 
weights include the inverse probability of HU selection (base weight), a household non-
interview, a within-household, a usually resided elsewhere, a person non-interview, and a 
first stage and second stage adjustment weight.  The weighting of wave 2 of the 
NESARC was adjusted to represent the wave 1 population, minus any attrition between 
the two waves as the result of incapacitation/institutionalization, death, 
deportation/permanently leaving the US or military service during Wave 2 assessment.57  
This was accomplished by including weighting adjustments for non-response, psychiatric 
diagnoses and sociodemographic factors.  This weighting readjustment resulted in there 
being no significant difference between wave 2 respondents and wave 2 respondents plus 
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wave 2 non-respondents on a number of baseline characteristics (age, gender, race-
ethnicity, socioeconomic status or the presence of any mood, anxiety, lifetime substance 
or personality disorder).57 Because of the complex sampling used in the NESARC, design 
effects need to be taken into account in the estimation of standard errors.  Inaccurate 
variance estimates will result if statistics appropriate for simple random samples are 
applied to complex samples like the NESARC without taking the sampling design into 
account.  The overall response rate for wave 1 (n= 43,093) was 81.2%23, 24with n= 34,653 
respondents participating in the 3-year follow up interview for a cumulative response rate 
70.2% at wave 2.25  All potential participants in the NESARC were informed in writing 
about the study.58 This written information described the nature of the survey, the 
statistical uses of the study information, the voluntary nature of their participation, and 
the Federal laws in place that protect the confidentiality of survey participants. Only 
those respondents who received this written information and consented to be interviewed 
were included in the study. Full ethical review and approval of the NESARC study was 
received from the U.S. Office of Management and Budget and from the U.S. Census 
Bureau.  A public use dataset of wave 1 is available for download on the internet from the 
National Archive24 and both wave 1 and wave 2 data sets were requested and received 
from NESARC principal investigators.  The use of these public use datasets has been 
deemed not to be human subject research and thus exempt from IRB approval by the 
University of Massachusetts Medical School’s Research Subjects Office. 
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II B. 2 The National Comorbidity Survey Replication: 
The National Comorbidity Survey Replication (NCS-R)59 was conducted between 
February 2001 and April 2003, thus overlapping the time period of the NESARC’s 
fielding.  Face-to-face computer-assisted personal interviews (CAPI) of 9282 respondents 
were conducted by professional survey interviewers (not federal employees).  The NCS-
R used the World Health Organization (WHO) Composite International Diagnostic 
Interview (CIDI) to assess psychiatric disorders.36  Previous versions of the CIDI had 
good to excellent kappa coefficients for most disorders in clinical and population samples 
though major depressive (k=0.66), bipolar I (k=0.61) and bipolar II (k=0.59) had only 
moderate test-retest reliability.60  The CIDI used in the NCS-R was divided into two 
parts.  Part 1 assessed core disorders including major depressive episode, manic and 
hypomanic episodes with Part 2 assessing services, consequences, and risk factors 
including substance use.  Respondents were interviewed for part 2 if they met criteria or 
met sub-threshold criteria and sought treatment for any part 1 disorder, or reported 
planning or attempting suicide.  A probability sub-sample selected those meeting sub-
threshold criteria for any disorder, sought treatment, had suicidal ideation or used 
psychotropic medication.  An additional probability sample of those not in the two 
previous groups were also selected and included in the part 2 interview.  The NCS-R used 
a four-stage area probability sample using data from the 2000 census.  The first stage 
involved primary sampling units based on metropolitan statistical areas, or counties 
defined by the census being selected by probabilities proportional to size (PPS).  The 
resulting sample included 46 non-self-representative PSUs with 13 self-representative 
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units split into 26 pseudo-PSUs for a total of 84 PSUs.  The second stage divided the 
PSUs into segments that had 50 to 100 housing units, these segments were selected by 
PPS.  The third stage selected households within the selected segments.  The final stage 
selected individuals within the household.  The weighting of the NCS-R sample accounts 
for non-response to full participation by using information aggressively collected on non-
responders by means of a short form.  Respondents to both part 1 and part 2 are weighted 
to be representative of the non-institutionalized English-speaking adult (18 and older) 
household population of the contiguous 48 US states.  Like the NESARC’s AUDADIS, 
the NCS-R’s CIDI was only administered in English.  As with the NESARC, the NCS-R 
is a public use data set not considered human subject research and exempt from IRB 
approval. 
 
II C. Methods: Approach 
The methodological approach for the study in this chapter is as follows.  First a 
determination of how DSM-IV criteria were applied in the two surveys was made.  
Differences between how the surveys applied DSM-IV criteria were identified.  Identified 
DSM-IV criterion differences between the two surveys were ‘reconciled’, where possible, 
by using available information in the NESARC to recode individual NESARC criterion 
and sub-criterion related question responses to more closely adhere to the CIDI 
operational schema.  So three separate series of estimates were made, one adhering to the 
NESARC/AUDADIS approach, the second being the reconciled NESARC/CIDI 
approach, and lastly the NCS-R/CIDI approach.  The effect of applying each successive 
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DSM-IV criterion for mania, hypomania and MDE were examining within each of these 
three modeling approaches.  The recalibration algorithm was then applied to the 
NESARC/CIDI and the NCS-R/CIDI models.  Furthermore survey ‘skip-outs’ within the 
mania and MDE sections of the two survey identified in the course of applying individual 
criterion, which created missing criterion and sub-criterion information were identified.  
This missing criterion information was coded as missing, and multiple imputation by 
chained equations (MICE)55 was applied to NESARC/CIDI and the NCS-R/CIDI models 
to assess the impact of this missing criterion information on bipolar prevalence estimates. 
 
II D. Survey Application of DSM-IV Criteria 
II D. 1 Manic Episode Criterion 
Both the NCS-R and the NESARC assessed mania, hypomania and major depressive 
episodes according to DSM-IV criteria.  Published algorithms of how the psychiatric 
disorders were operationalized for the NCS-R have been published,20but algorithms of 
how the psychiatric disorders were operationalized in the NESARC have not.61  
Determining the algorithms for the NESARC involved examination of the relevant 
research articles, 16, 62survey materials,28 personal correspondence,38, 63 and/or inference 
from NESARC investigators constructed variables. 
 
To define the cohorts of those meeting individual DSM-IV criterion for a manic episode 
for both the NESARC/AUDADIS and NESARC/CIDI approaches individual survey 
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responses from the High Mood section of the AUDADIS were used.  Likewise with the 
NCS-R individual questions from the screening and manic section of the CIDI were used 
to operationalize individual manic episode criterion (Appendix A).  DSM-IV manic 
episode criterion A is operationalized by the AUDADIS with the required endorsement of 
either a week or more of ‘extremely excited, elated or hyper mood’ such that other people 
were concerned about or thought was uncharacteristic of the respondent, or a week or 
more of irritable mood.  The CIDI likewise requires a week or more of abnormally and 
persistently elevated, expansive, or irritable mood, but the CIDI also includes endorsing 
hospitalization as a means of meeting criterion A (i.e. hospitalization eliminates the 
requirement of a week or more of mood duration).  Manic episode criterion B symptom 
questions (Table 2.1) for both the AUDADIS and the CIDI closely adhere to the DSM-IV 
and were assessed for the episode when the respondent’s mood was the most elevated or 
irritable.  Both the AUDADIS and the CIDI require endorsement of at least three of the 
seven Criterion B symptoms for those endorsing elevated mood and at least four 
symptoms for those only endorsing irritable mood as prescribed by the DSM-IV.  The 
AUDADIS does not systematically assess Mixed Episodes among all respondents and as 
such the requirement that the symptoms of a manic episode do not meet criteria for a 
Mixed Episode (i.e. criterion C) was not implemented.  Similarly the CIDI does not 
operationalize criterion C.   No differences between the NESARC/AUDADIS and 
NESARC/CIDI approaches are present for DSM-IV manic episode criterion A, B and C.  
Respondents to the NESARC who did not respond either ‘yes’ or ‘no’ to any of the manic 
episode or MDE stem questions (i.e. criterion A questions) were considered to have  
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NCS-R NESARC
1:  Did you become so restless or fidgety that you paced up 
and down or couldn’t stand still?
1:  Feel so restless that you fidgeted, paced, or couldn’t sit 
still?
2:  Become so physically restless that it made you 
2:  Were you a lot more interested in sex than usual, or did 
you want to have sexual encounters with people you wouldn’t 
ordinarily be interested in?
3:  Become more sexually active than usual or have sex with 
people you normally wouldn’t be interested in?
3:  Did you become overly friendly or outgoing with people?
4:  Did you try to do things that were impossible to do, like 
taking on large amounts of work?
4:  Become more active than usual, at work, at home, or in 
pursuing other interests?
5:  Did you do anything else that wasn’t usual for you - - like 
talking about things you would normally keep private, or 
acting in ways that you’d usually find embarrassing?
6:  Did you talk a lot more than usual or feel a need to keep 
talking all the time? 5:  Find you were more talkative than usual?
6:  Talk so fast that people had trouble understanding you or 
couldn’t get a word in edgewise?
7:   Did you find it hard to keep your mind on what you were 
doing?
7:  Have trouble concentrating because little things going on 
around you easily got you off track?
8:  Did you constantly keep changing your plans or activities?
9:  Did your thoughts seem to jump from one thing to another 
or race through your head so fast you couldn’t keep track of 
them?
8:  Find that your thoughts raced so fast that it was hard to 
follow your own thoughts?
9:  Find that your thoughts raced so fast that you couldn’t 
keep track of them?
10:  Did you sleep far less than usual and still not get tired or 
sleepy? 10:  Need much less sleep than usual?
11:  Did you get involved in foolish investments or schemes 
for making money?
11:  Do anything unusual that could have gotten you into 
trouble - like buying things you couldn’t afford or didn’t 
need, making foolish decisions about money, or driving 
recklessly?
12:  Did you spend so much more money than usual that it 
caused you to have financial trouble?
13:  Did you do reckless things like driving too fast, staying 
out all night, or having casual or unsafe sex?
12:  Do anything that you later regretted - like spending time 
with people you normally wouldn’t be interested in?
14:  Did you have a greatly exaggerated sense of self-
confidence or believe you could do things you really couldn’t 
do?
13:  Feel that you were an unusually important person or that 
you had special gifts, powers, or abilities to do things that 
most other people couldn’t do?
15:  Did you have the idea that you were actually someone 
else, or that you had a special connection with a famous 
person that you really didn’t have?
13A:  Psychotic feature defined as presents of grandiosity 
(above question, for use in NESARC/CIDI approach) AND a 
history of psychotic diagnosis or episode.
Table 2.1: DSM-IV Manic and Hypomanic Symptoms by Corresponding Survey Symptom Questions
Increase in goal-oriented activity (either socially, at work or school, or sexually) or psychomotor agitation
More talkative than usual or pressure to keep talking
Inflated self-esteem or grandiosity/delusional/psychotic
Distractibility
Flight of ideas or subjective experience that thoughts are racing
Engaging in unrestrained buying sprees, sexual indiscretions, or foolish business investment
Decreased need for sleep
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refused these sections and were coded as missing.  For the NCS-R refusal information 
was available and those who refused mania screening and/or stem questions were coded 
as missing. 
II D. 2 Reconciling AUDADIS Manic Episode Criterion D with CIDI Approach: 
The AUDADIS asks five questions to assess DSM-IV manic episode criterion D.  DSM-
IV manic episode criterion D requires that the mood disturbance be severe enough to 
cause marked social or occupational impairment or to necessitate hospitalization or have 
psychotic features.  The questions (Appendix B, questions 7a1 to 7a5)28 were asked 
specifically about the most elevated or irritable lifetime mood episode, the same episode 
for which criterion B symptoms were assessed.   Respondents endorsing three or more 
manic symptoms were asked: 1) whether they were uncomfortable or upset by their 
manic symptoms (‘uncomfortable with symptoms’), 2) did they have “any serious 
problems getting along with other people - like arguing with your friends, family, people 
at work or anyone else?” (‘social impairment’), 3) “Did you have any serious problems 
doing things you were supposed to do - like working, doing your schoolwork, or taking 
care of your home or family?” (‘occupational impairment’), 4) they were asked “Did you 
have trouble getting things done?” (‘difficulty completing tasks’), and lastly 5) “Did you 
have any legal trouble - like being arrested, held at the police station or put in jail?” 
(‘legal involvement’).   The NESARC/AUDADIS approach requires the positive 
endorsement of any one of the five impairment questions to satisfy Criterion D.  
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In the CIDI criterion D, or impairment, is assessed among those who endorses 3 or more 
or the 15 criterion B symptom questions.20  Only one question is asked to all the 
respondents endorsing 3 or more symptom questions.  This question, M9, asks “How 
much did these episodes ever interfere with either your work, your social life, or your 
personal relationships – not at all, a little, some, a lot, or extremely?”64  Those endorsing 
either ‘some’, ‘a lot’, or an ‘extreme’ amount of impairment continue further in the CIDI 
Mania section and are asked, among other things, more criterion D and criterion E 
questions.  It is important to note at this juncture that those endorsing ‘not at all’ or ‘a 
little’ to question M9 are skipped out of the Mania section altogether.  If criterion D was 
only being assessed with question M9 this would not be a problem but other questions 
capturing important and required DSM-IV criterion D features are not taken into account 
by the skip out at this question.  Indeed the CIDI uses not only question M9 but other 
questions assessing impairment in the past 12 months (see Appendix A), hospitalization, 
seeing a mental health professional and psychotic features to operationalize criterion D.  
Questions asked after question M9 capture lifetime criterion D traits namely 
hospitalization and seeing a mental health professional.  Criterion E is also assessed after 
M9 so those skipped out at M9 can not satisfy this criterion.  Criterion E for manic 
episode (criterion F for hypomania) requires that the mood episode not be due to the 
direct physiological effects of substances or be the result of a general medical condition.  
The CIDI requires assessment of substance or illness induced mood episodes for criterion 
E to be coded as either present or absent.  The CIDI uses questionnaire responses as a 
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screener with clinicians evaluating freeform responses to determine if mood episodes 
were illness or substance induced. For the imputation analysis, hospitalization, seeing a 
mental health professional and criterion E are coded as missing among those that 
endorsing ‘not at all’ or ‘a little’ to question M9 and were skipped out of the mania 
section. 
 
For the reconciled NESARC/CIDI model, criterion D was considered to have been meet 
by the endorsement of either social or occupational impairment as described above, or the 
presents of psychotic features, or the endorsement of hospitalization, or seeing a mental 
health professional, or having had a mania related emergency room visit, or whether they 
were ever prescribed medication for mania.  The CIDI does not ask about emergency 
room visits or prescriptions for mania but as these both involve seeing a mental health 
professional, a CIDI measure of impairment, and as such they were included in the 
reconciled NESARC/CIDI model.  The AUDADIS impairment questions involving 
‘being uncomfortable with manic symptoms’, ‘having trouble getting things done’ and 
‘legal involvement’ were not considered sufficient, standing alone, to necessarily 
constitute impairment in the context of the CIDI approach or DSM-IV criterion D.  The 
‘being uncomfortable or upset’ question captures an ambiguous level of distress.  Distress 
alone is not a part of DSM-IV criteria for mania.  Distress could be considered impairing 
but the social and occupational impairment questions assess this trait.  The ‘having 
trouble getting things done’ question is vague enough that it may misclassify some as 
being occupationally impaired who subsequently fail to endorse the ‘occupational 
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impairment’ question.  Legal involvement was also not used as an impairment measure as 
it was not used in the CIDI and may also misclassify as manic some respondent who 
experienced legal involvement during a hypomanic episode (e.g. a traffic violation with 
outstanding warrants). As the AUDADIS grandiosity/delusional question (i.e Table 2.1, 
question 13) is not specific to delusional or psychotic features additional information was 
used to define psychotic features.  All respondents to the NESARC were asked: “Did a 
doctor or other health professional EVER tell you that you had schizophrenia or a 
psychotic illness or episode?”28 (coded 1=yes, 0=no). The psychotic feature trait for 
NESARC/CIDI modeling approach was defined as the endorsement of the 
grandiosity/delusional question and the psychotic illness or episode question.  It should 
be noted that both the NESARC and the NCS-R do not apply hierarchy rules to their 
definitions of mania and bipolar disorder with respect to schizophrenia spectrum 
disorders (i.e. schizophrenia spectrum disorders were not used to exclude bipolar 
spectrum disorders). 
 
II D. 3 AUDADIS DSM-IV Manic Episode Criterion E, Hypomanic Episode 
Criterion F: 
As previously mentioned the CIDI uses questionnaire responses to screen for illness or 
substance induced mood episodes and clinician evaluation of freeform responses to 
determined if the mood episodes meet manic episode criterion E (hypomanic episode 
criterion F).  For the AUDADIS, questionnaire logic and variables constructed by 
NESARC investigators and included in the NESARC data file were used to infer how 
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substance and illness induced mood episodes were identified.  A variable (nmandxlife) 
representing manic episode before the application of criterion E (mania meeting criterion 
A, B and D) was included in the data set. Variables indicating manic episodes with illness 
(dnmandxsni12 and dnmandxsnip12) and substance use (nmandxsns12 and 
nmandxsnsp12) as a cause being ruled out in the last 12 months and prior to the last 12 
months respectively were also included in the data set.  From these variables one can 
identify which respondents the NESARC investigators identified as meeting lifetime 
manic episode criterion A, B and D as well those excluded for substance or illness 
induced mood episodes.  The following approach was used to operationalize criterion E 
for both the NESARC/AUDADIS and NESARC/CIDI approaches.  To fail to meet 
Criterion E respondents needed to have had all of their lifetime manic episodes either 
illness induced or substance induced.  Episodes were considered illness induced if the 
respondent reported that a doctor or health professional told them that all of their 
episodes were related to a physical illness or medical condition (in both the past year and 
prior to the past year if applicable).   To fail Criterion E for substance use a respondent 
would need to do all of the following: 1) report that all episodes followed substances use 
or withdrawal, 2) report stopping substance use or stopped experiencing withdrawal 
symptoms for at least a month and, 3) report manic symptoms did not continue after the 
secession of substance use or withdrawal symptoms for all episodes (again, in both the 
past year and prior to the past year if applicable).  These episodes can reasonably be 
explained better by substance use or withdrawal and as such fail to meet Criterion E.  For 
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the NESARC/AUDADIS, NESARC/CIDI and the NCS-R/CIDI models a lifetime DSM-
IV manic episode was defined as positive if respondents meet criterion A, B, D and E. 
 
II D. 4 Survey Application of DSM-IV Hypomanic Episode Criterion 
Both the AUDADIS and the CIDI assessed hypomanic episodes with the same set of 
questions that were used to assess manic episodes.  DSM-IV hypomanic episode criterion 
A requires a distinct period of persistently elevated, expansive, or irritable mood, lasting 
at least 4 days.  The AUDADIS does not assess mood episodes less than one week in 
duration.  For the AUDADIS manic episode criterion A and hypomanic episode criterion 
A are the same.  The CIDI operationalization of hypomanic episode criterion A includes 
mood episodes as short as four days.  For both the AUDADIS and the CIDI hypomanic 
and manic symptom criterion (criterion B) are the same.  DSM-IV hypomanic episode 
criterion C requires that the mood episode represent an unequivocal change in 
functioning.  This unequivocal change in functioning is considered satisfied in the 
AUDADIS by the endorsement of any of the High Moods stem questions (Appendix B, 
questions 1, 2 or 3) the same question that constitute mania/hypomania criterion A. In the 
CIDI lifetime unequivocal change in functioning in effectively assessed by only one 
question, M9 (Appendix A), other questions assess functioning in the past 12 months and 
seeing a mental health professional is later used as an exclusion criterion (hypomania 
criterion E).  For the CIDI question M9 endorsement of ‘some’ interference with work, 
social life, or personal relationships constitutes the unequivocal change in functioning 
requirements of hypomania criterion C (note that ‘a lot’ or an ‘extreme’ amount of 
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interference reported at M9 constitutes marked impairment, hypomanic episode criterion 
E).  DSM-IV hypomanic episode criterion D that the mood disturbance and the 
unequivocal change in functioning be observed by others is not operationalized by either 
the AUDADIS or the CIDI. 
 
DSM-IV hypomanic episode criterion E requires that the unequivocal change in 
functioning of criterion C not be severe enough to cause marked impairment in 
occupational or social functioning, require hospitalization or include psychotic features 
(i.e. does not meet the manic episode level of marked impairment, manic episode 
criterion D).  For the NESARC/AUDADIS model endorsement of any of the AUDADIS 
manic episode impairment questions (Appendix B, questions 7a1 to 7a5) resulted in 
failure to meet hypomanic episode criterion E.  For the NESARC/CIDI approach 
hypomanic episode criterion E was considered to have been meet if all of the following 
were not endorsed: social or occupational impairment as described above, the presence of 
psychotic features, hospitalization, seeing a mental health professional, having had a 
mania related emergency room visit, and having been prescribed medication for mania.  
For the NCS-R/CIDI approach those meeting manic episode criterion D as described 
above fail to meet hypomanic episode criterion E (coded failure=0, meet hypomanic 
criterion A, B and C=1).  Hypomanic criterion F (i.e. not illness or substance induced) is 
operationalized in the same way as manic episode criterion E as described above.  For the 
NESARC/AUDADIS, NESARC/CIDI and the NCS-R/CIDI models DSM-IV hypomanic 
episode was defined as those respondents meeting criterion A, B, C, E and F.  
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Additionally in the NCS-R/CIDI hypomanic episode model those that meet criteria for a 
manic episode but for the condition that their episode lasted between 4 and 6 days (with 
no hospitalization) and as such did not meet criteria for a manic episode, are considered 
hypomanic in the CIDI schema. 
 
II D. 5 Survey Application of DSM-IV Major Depressive Episode Criterion: 
DSM-IV major depressive episode criterion A requires 5 or more of 9 symptoms to be 
present for at least 2 weeks and that at least one of the 5 or more symptoms is either 
depressed mood or anhedonia (i.e. loss of interest or pleasure).  In the AUDADIS lifetime 
depressed mood and anhedonia are assessed by questions 1 and 2 of the Low Mood I 
section (Appendix C).  The remaining other 7 symptoms (weight change, sleep 
disruption, psychomotor agitation or retardation, fatigue, feelings of worthlessness, loss 
of concentration and suicidality) are assessed with 19 separate questions.  Examination of 
the Low Mood I section shows that after the symptom questions are asked ‘Check Item 
4.3’ requires 4 of the previously mentioned 7 symptoms (not including depressed mood 
and/or anhedonia) to proceed further in the assessment of other major depressive episode 
criterion.  Respondent endorsing both lifetime depressed mood and anhedonia and 3 of 
the remaining 7 symptoms for a total of 5 endorsed symptoms are skipped out of the 
major depressive episode section of the AUDADIS.  This un-assessed group represents 
respondents who most probably meet MDE criterion A (but for the ambiguity of the 
concurrency of the depressed mood and anhedonia as the questions ask about lifetime 
occurrence) and are missing remaining DSM-IV criterion information.  For the 
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imputation analysis relevant criterion questions (described in detail below) are coded as 
missing among this un-assessed group. Imputing responses to these missing criterion 
questions allows a probabilistic assessment of the impact of this group on MDE and 
Bipolar II prevalence estimates.  In the CIDI implementation of MDE criterion A 
symptoms are assessed within the same mood episode and the 9 MDE symptoms are 
operationalized with 24 separate questions (Appendix D).   MDE criterion A is satisfied 
in the NESARC/AUDADIS, NESARC/CIDI, and NCS-R/CIDI models when 5 or more 
symptoms are endorsed. 
 
DSM-IV MDE criterion B, which requires that the symptoms not meet criteria for a 
Mixed Episode, was not implemented in either the NESARC or the NCS-R.  DSM-IV 
MDE criterion C requires that the symptoms cause clinically significant distress or social 
or occupational impairment.  The AUDADIS assessed MDE criterion C with 8 questions: 
2 distress questions and 6 impairment questions (all yes/no questions, Appendix C 
questions 5 (1) - 5(8)).  The CIDI assessed MDE criterion C with 9 questions: 4 distress 
related questions and 5 impairment questions (most on a 4 level Likert scale or 10 level 
visual analog scale, Appendix D).  For the NESARC/CIDI implementation two changes 
were made to the NESARC/AUDADIS approach.  First those reporting being 
uncomfortable or upset ("Were you uncomfortable or upset by your low mood or any of 
these other experiences?") but not reporting being very troubled ("Were you very 
troubled because of the way you felt at that time or did you often wish you could get 
better?") were not considered distressed as they were likely uncomfortable but not very 
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troubled by their symptoms, and as such not rising to a clinically significant level of 
distress.  Secondly, those reporting being less active ("Did you find you did a lot less than 
usual or were less active?") but not endorsing "find(ing) you couldn't do the things you 
usually did or wanted to do?", were not considered impaired as their inactivity was likely 
not indicative of a clinically significant level of impairment.  Both the AUDADIS and the 
CIDI applied the same approach to determining illness and substance induced exclusions 
(i.e. failing MDE criterion D) for MDE as was applied to mania criterion E and 
hypomania criterion F (reference above). 
 
DSM-IV MDE criterion E requires the following: That bereavement not better account 
for symptoms, such that after the death of a loved one, the symptoms need to persist for 
longer than 2 months or be characterized by marked functional impairment, suicidal 
ideation, morbid preoccupation with worthlessness, psychomotor retardation, or 
psychotic symptoms.11  The AUDADIS assesses bereavement but the CIDI does not.  For 
the AUDADIS assessment of bereavement, questionnaire logic and variables constructed 
by NESARC investigators and included in the NESARC data file were used to infer how 
it was operationalized.  A variable (majordeplife) representing lifetime MDE after 
exclusions for bereavement (MDE criterion E applied) but before the application of MDE 
criterion D (MDE criterion A, B and E) was included in the data set.  As previously 
mentioned respondents meeting MDE criterion A and B can be identified from survey 
question responses.  Those meeting MDE criterion A and B but not represented in the 
majordeplife variable were considered to be those identified as ‘bereaved’ by the 
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NESARC investigators.  Variables indicating MDE with illness (dmajordepsni12 and 
dmajordepsnip12) and substance use (majordepsns12 and majordepsnsp12) as a cause 
being ruled out in the last 12 months and prior to the last 12 months respectively were 
also included in the data set which allow identification of those meeting MDE criterion D 
in the same manner as use for manic and hypomanic episodes.  Comparing those 
identified as bereaved to individual survey responses one can infer a general approach to 
the operationalization of bereavement in the AUDADIS.  The simplest operationalization 
that can be inferred relies on re-coded variables as found in the NESARC data set and is 
as follows: respondents that report one episode lasting less than 2 months needed to 
endorse that the episode began after someone close to them died.  Respondent reporting 
more than one episode needed to endorse that all of their episodes that lasted “less than 2 
months” only began after some one died.  The NESARC/AUDADIS approach relies only 
on the positive endorsement of these bereavement responses to identify those excluded 
from a MDE diagnosis due to bereavement.   The AUDADIS does not explicitly exclude 
those who earlier in the survey endorsed episodes of greater than 2 months (at least 
among those with more than one episode), or endorsed impairment, morbid 
preoccupation with worthlessness, suicidal ideation, psychomotor retardation, or 
psychotic symptoms (not assessed in either the AUDADIS or the CIDI MDE sections).  
For the NESARC/CIDI approach (or for this criterion it may be more apt to it call the 
NESARC/DSM-IV approach as bereavement was not assessed in the CIDI) those not 
endorsing that their longest episode was 9 weeks or shorter in duration were ruled out for 
a bereavement exclusion.  Additionally, in keeping with the DSM-IV, worthlessness, 
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suicidal ideation, psychomotor retardation and impairment (as defined above) were 
applied to rule out bereavement as an exclusion from a MDE diagnosis.   
 
II E.  National Comorbidity Survey-Replication Clinical Re-evaluation and 
Recalibration: 
A recalibration algorithm for bipolar spectrum disorders based on CIDI diagnoses and 
individual CIDI questions has been published.20  This recalibration algorithm reclassifies 
the CIDI diagnoses of BDI and BD II so as to increase these diagnoses’ concordance with 
a weighted clinical reassessment sub-sample administered the lifetime non-patient 
version of the Structured Clinical Interview for DSM-IV (SCID).34  This recalibration 
algorithm tightens up the criteria to meet BDI and BD II and creates a sub-bipolar group 
made up of those meeting the ‘old’ CIDI criteria for BDI or BD II but failing to meet the 
new definition.  The algorithm creates a high threshold for meeting BDI, requiring the 
following conditions be meet: 1) CIDI implemented DSM-IV criteria for mania, 2) 
endorse >=6 of the 7 DSM-IV manic episode criterion B symptoms as well as 2 or more 
of the following ‘super-symptoms’: increased libido, being overly friendly or outgoing, 
involved in foolish investments, over spending leading to financial trouble or 
psychotic/delusional features.  For the NESARC, foolish investments and over-spending 
are included in the same question (Table 2.1) the endorsement of which was considered 
to be equivalent to two ‘super-symptoms’.    The published algorithm states “at least 6 
symptoms in the M7 series (DSM_MAN_OLD Criteria B1-B7)”20 which other 
researchers65 have interpreted to mean individual symptom questions in the M7 series as 
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opposed to endorsed DSM-IV criterion symptoms.  Applying a threshold of 6 or more 
endorsed DSM-IV criterion symptoms results in Bipolar I case counts being in accord 
with published counts as included in public release data set.  The algorithm is described 
in full in Appendix A.  For Bipolar II the algorithm requires that the new definition of 
Bipolar I not be meet and that the CIDI criteria for mania (pre-algorithm definition) be 
meet and the respondent experienced a MDE, euphoria (elevated mood) and racing 
thoughts.  Bipolar II is also meet if the CIDI definition of bipolar II is meet (hypomania 
plus a history of a MDE) and the hypomanic episode is at least 14 days long and at least 2 
of the “super symptoms” are endorsed.  Sub-threshold Bipolar Sub is defined as anyone 
left meeting the pre-algorithm CIDI definitions of mania and hypomania and not 
represented in the newly defined Bipolar I and Bipolar II groups. 
 
II F. MICE: Multiple Imputation by Chained Equations 
Multiple imputation (MI)66 is a probabilistic approach for handling missing data.  The 
fundamental approach to MI is to use the distribution of observed information (i.e. data) 
to predict a set of reasonable values for the missing information.67  The predicted set of 
plausible values includes a random selection process to reflect their uncertainty. Multiple 
data sets containing these predicted values (e.g. ‘imputed’ data sets) with random 
variations are produced and then analyzed individually but in the same manner so as to 
produce a set of parameter estimates.  The Stata user written program ICE was used to 
produce the multiple imputed data sets used in this study.68-72  Lastly, these estimates are 
combined to produce the resulting overall estimate, variance and confidence intervals.  
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The Stata user written program MIM was used to produce the overall estimates for this 
study.73  Rubin’s rules are used to combine m number of estimates into an overall 
estimate.74  Rubin’s rules address both within-imputation uncertainty (one imputed data 
set’s variability of the estimate) and between-imputation uncertainty (representing the 
variability due to the missing data).67, 74  Consider   is an estimate of interest (e.g. a 
mean) obtained from the j th imputed data set j and Wj is the estimated variance of . 
The average of the estimates is the combined estimate : 67 
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Multiple imputation, as operationalized by the ICE procedure, uses multiple imputation 
by chained equations (MICE).55  MICE involves the following general process: 55, 67 first 
a variable with missing values, A1 say, is modeled (e.g. logit, ordinal or multinomial 
logistic regression, linear regression) with all other variables A2, . . . , Ak, but limited to 
data with the observed A1. Missing values in A1 are replaced by random draws from the 
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predicted distribution of A1. Then, A2 the next variable with missing data, is modeled 
with all the other variables A1, A3, . . . , Ak , restricted to individuals with the observed 
A2, but now also using the previously imputed values of A1. As with A1, missing values 
in A2 are replaced by random draws from the predicted distribution of A2. This 
procedure is repeated for all the variables with missing values.  To produce a stable result 
this procedure is repeated several times (e.g. 10 or 20) to generate a single imputed data 
set.  This whole procedure is repeated multiple times to produce multiple data sets.  MI in 
general and MICE in particular assumes the missing data are missing at random (MAR- 
the probability of data being missing is not a function of unobserved information, 
conditional on the observed information).  This assumption is not an unreasonable one in 
the context of this study.  A considerable proportion of the missing criterion information 
in both the NESARC and the NCS-R is a by product of skip patterns within diagnostic 
sections. These skip patterns are based on observed characteristics so the missing data are 
less likely to be missing not at random (MNAR- data missing probability is dependent on 
the unobserved data, conditional on the observed information).  
 
II F. 1 MICE and the NESARC: 
MICE was applied to the NESARC data set to assess the impact of missing criterion 
information on the prevalence estimates of bipolar I (mania), bipolar II (hypomania and 
MDE), hypomania and MDE.  Variables used for imputation included demographic 
variables, mania and major depressive episode related variables, and psychiatric 
comorbidity variables.  The demographic variables have no missing values as the 
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NESARC investigators assigned or imputed any missing values in these variables.56  The 
demographic variables included: gender (male=1, female=0), race/ethnicity (1=White, 
Not Hispanic or Latino, 2=Black, Not Hispanic or Latino, 3= American Indian/Alaska 
Native, Not Hispanic or Latino, 4= Asian/Native Hawaiian/Pacific Islander, Not Hispanic 
or Latino, 5=Hispanic or Latino), age cohort (1= 18-25, 2= 26-35, 3= 36-45, 4= 46 and 
older), educational status (1= less than High School, 2= High School or GED, 3= some 
college/Associate or Technical degree, 4= greater than or equal to a bachelor's degree), 
marital status (1=Married or living with someone as if married (not currently married or 
separated from another person), 2= Divorced or Separated, 3=Widowed, 4= Never 
Married), personal income quartiles in dollars (1= ≤ 8,800, 2= 8,800 to ≤ 20,000, 3= 
20,000 to ≤ 36,000, 4= ≥ 36,00), urbanicity (1= Urban [metropolitan statistical area 
(MSA) , in central city], 2= Suburban [MSA, not in central city], 3= rural [not in MSA]), 
and census region (1= Northeast, 2= Midwest, 3= South, 4= West). 
 
Manic episode related variables necessary to operationalized DSM-IV criteria and to 
apply the CIDI recalibration algorithm were included in MICE analysis.  This included 
indicators of individual survey responses including indicators for the manic sections three 
stem questions (s5q1, s5q2 and s5q3) which were coded 1=yes and 0 =non-endorsement 
(i.e. ‘no’ or ‘unknown’) with those failing to explicitly endorse any of these three 
question (i.e. no ‘yes’ or ‘no’ responses) being coded as missing (e.g. complete absence 
of any ‘yes’ or ‘no’ responses for all three questions being interpreted as refusal of the 
whole manic section).  All the other variables in the manic section are coded as missing if 
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all of these stem questions (i.e. s5q1, s5q2 and s5q3) are ‘unknown’ with subsequent 
‘unknown’ responses for all other questions interpreted as non-endorsement and coded as 
0.  Other individual question indicators included survey questions s5q6a9, s5q6a11 and 
s5q6a12 which correspond to questions 3, 11 and 12 in Table 2.1 respectively.  The seven 
DSM-IV manic episode criterion B symptoms were coded to separate indicators with the 
indicators for s5q6a11 and s5q6a12 used to passively impute (e.g. used to define) the 
excessive engagement in pleasurable activities symptom.  An indicator for having three 
or more symptoms was passively imputed within the ICE procedure from the symptom 
count.  This indicator was use to restrict the imputation models of the impairment (both 
NESARC/CIDI and NESARC/DSM-IV approaches), substance induced and illness 
induced variables to only respondents that logical would have been asked about these 
feature but for missing responses.  The impairment, substance induced and illness 
induced variables, as well as the psychotic variable, conformed to the NESARC/CIDI 
coding scheme as described above.  A separate impairment indicator conforming to the 
NESARC/DSM-IV schema described above was also included.  The length of the manic 
episode is necessary to apply the CIDI recalibration algorithm, this was coded as (1= 1-2, 
2= 3-17, 3= ≥ 18 weeks) and were imputed by ordinal logistic regression.  Log 
transformed age of mania onset use was also included and imputed by linear regression. 
 
For MDE in the NESARC the depressed mood and anhedonia questions are the stem 
questions for the Low Mood I section and failure of respondents to provide a yes or no 
response to both of these question results in them being coded as missing. Depressed 
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mood and anhedonia as well as the remaining seven DSM-IV MDE symptoms were 
coded to separate dichotomous indicators.  An indicator of endorsement of five or more 
symptoms was passively imputed within the ICE procedure by counting the number of 
endorsed symptoms.  This indicator was used to restrict the imputation models of the 
impairment related, substance and illness induced variables, as described above, to only 
those who logically would been asked these criterion question under the assumption that 
all the symptoms were contemporaneous.  Log transformed age of MDE onset use was 
also included and imputed by linear regression. 
 
Other variables used in the MICE analysis included separate indicators for substance use 
variables: alcohol abuse (no dependence), alcohol dependence, cannabis abuse (no 
dependence), cannabis dependence, other substance abuse or dependence, other drug use 
and nicotine dependence.  Other variables include the anxiety disorders variables panic 
disorder or agoraphobia, social phobia, specific phobia and generalized anxiety disorder.  
A separate indicator was coded for dysthymia.  For those experiencing any illness 
induced anxiety disorders or dysthymia were coded to a variable to capture this effect.  
Likewise for those experiencing any substance induced anxiety disorders or dysthymia.  
Separate variables were coded for antisocial, paranoid, schizoid, avoidant, dependent, 
obsessive–compulsive and histrionic personality disorders.  For the NESARC imputation 
using ICE all the above variables were considered for use in modeling ever other 
variable.  All imputation variable models were assessed for high degrees of correlation of 
the predictive variables by running them as linear regress models and excluding 
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predictors with variance inflation factors (VIF) of 10 or more.  This was done to address 
collinearity among the predictive variables within individual predictive models.  The 
number of NESARC imputed data sets created and used in the analysis was n=100.67, 75  
Individual criterion variables within each imputed data set were used to specify mania, 
hypomania, MDE, Bipolar I, II and sub-threshold Bipolar disorders.  These estimates 
were aggregated using the MIM procedure. 
 
II F. 2 MICE and the NCS-R: 
In a similar fashion as the NESARC, the NCS-R imputation used demographic variables, 
mania and major depressive episode related variables, and psychiatric comorbidity 
variables.  The demographic variables included: gender (male=1, female=0), 
race/ethnicity (1=White, Not Latino, 2=African Americans, Afro-Caribbean, 3= Mexican, 
all other Hispanics, 4= Asian, other), age cohort (1= 18-25, 2= 26-35, 3= 36-45, 4= 46 
and older), educational status (1= less than 11 years, 2= 12 years, 3= 13 to 15 years, 4= 
16 years or greater), marital status (1=Married or living with someone as if married, 2= 
Divorced or Separated or Widowed, 3= Never Married), and census region (1= Northeast, 
2= Midwest, 3= South, 4= West).   
 
The NCS-R manic episode variables included separate dichotomous indicators for 
elevated and irritable mood and seven indicators for each of the criterion B symptom and 
the psychotic feature as described above.  All those explicitly refusing (refusal 
information is available in the NCS-R, unlike the NESARC) individual responses were 
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coded as missing, those endorsing dichotomous questions as ‘don’t know’ were coded as 
0.  Stem question refusal was defined as refusing the manic screening question (M1) and 
refusing either the elevated mood (SC24) or the irritable mood questions (SC25).  
Episode length was coded to an ordered categorical indicator (1=4-6 days, 2=7-13 days, 
3= 14 or more days) and modeled with ordinal logistic regression.  Individual indicators 
for survey questions involving foolish investments/money making (M7K) and financial 
trouble/spending sprees (M7L) were coded to separate indicator variables.  Those 
endorsing hypomania and mania criterion C, seeing a mental health professional, 
experiencing hospitalization or having a manic/hypomanic episode substance or illness 
induced were coded to separate indicators and considered missing if ‘not at all’ or ‘a 
little’ to question M9 were endorsed, individual question were refused or the stem 
questions were refused. 
 
Psychiatric comorbidity related variables used in the imputation of the NCS-R data 
included the endorsement of MDE symptoms (depressed mood, anhedonia, weight 
loss/gain, insomnia, psychomotor retardation, fatigue, worthlessness, indecisiveness, 
suicidality, distress, impairment, duration and an illness or substance induced indicator).  
Other psychiatric comorbidity related variables included indicators for respondents 
meeting DSM-IV criteria for GAD, agoraphobia, social phobia, specific phobia and panic 
attack.  The endorsement of being hospitalized for a mental health or substance related 
issue, suicidality (generally, outside the context of the MDE questions), the use of 
antipsychotic medication, stimulants, sedatives, tranquilizers and anti-depressives were 
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all coded to separate indicators.  Individual psychiatric disorder variables were 
considered missing if the stem questions for their corresponding diagnostic section of the 
CIDI were refused.  It should be noted that substance abuse and dependence in the NCS-
R was assess in part 2 of the survey, a sub-population, and as such these variables were 
not used in the full population imputation analysis.   
 
The implementation of ICE with the NCS-R specified the prediction variables for 
individual imputed variables be significant related (p<0.1) and were selected by 
backwards stepwise selection.  The number of imputed data sets created and used in the 
analysis was n=50.67, 75  As was done with the NESARC imputation, individual criterion 
variables within each imputed data set were used to specify mania, hypomania, MDE, 
Bipolar I, II and sub-threshold Bipolar disorders.  These estimates were then aggregated 
using the MIM procedure. 
II G. Results: 
II G. 1 Manic episode 
The results of applying successive DSM-IV manic episode criterion to the NESARC and 
NCS-R data sets are shown in Table 2.2.  For the NESARC 2.3% (n=1014) of the 
respondents did not provide any valid (i.e. yes or no) responses to the manic diagnostic 
section stem questions.  Subsequent manic and hypomanic episode and criterion 
prevalence estimates are based on a population of 42,079 respondents.  For the NCS-R, 
only three respondents (0.04%) refused the manic stem questions with manic and  
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hypomanic episode and criterion prevalence estimates based on a population of 9,279 
respondents.  The application of criterion D (i.e. impairment criterion) is the only 
difference between the AUDADIS/NESARC and the AUDADIS/CIDI approaches.  The 
0.5% difference in prevalence of those meeting criterion A, B and D between the two 
approaches is significant (p<0.001).  Significant differences are also seen between the 
AUDADIS/CIDI and the NCS-R/CIDI approaches.  Differences which remain relatively 
stable after the application of criterion A and B.  It should be noted that the 
AUDADIS/NESARC results in n=1414 manic episode cases and that this differs from the 
number published16 by the NESARC investigators (n=1411).  The three differing cases 
all failed to positively report the number of individual episodes they experienced and if 
their first episode occurred in the last 12 months (i.e. unknown responses) and were 
assessed for illness and substance induced episodes only for the period prior to the last 12 
months.  These three cases meet DSM-IV manic episode criterion A, B and D and 
reported that all of their episodes prior to the last 12 months were not either substance or 
illness induced and as such were considered to have meet DSM-IV criteria for a manic 
episode based of the best available information.  The NESARC operationalization of 
manic episode criterion E required information from both time periods for those with an 
ambiguous number of episodes and onset. 
II G. 2 Hypomanic episode 
The results of applying successive DSM-IV hypomanic episode criterion are shown in 
Table 2.3.  For the NESARC, as seen with mania, no differences between the 
AUDADIS/NESARC and the AUDADIS/CIDI approaches are seen until criterion E (not 
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meeting marked impairment, manic criterion D) is applied.  The 0.4% difference in 
prevalence found between the two criterion approaches is significant (p<0.001).  This 
difference remains after applying the full hypomanic episode criteria (criterion A, B, C, E 
and F).  Considerable differences are seen between the AUDADIS/CIDI and the NCS-
R/CIDI approaches starting at criterion E (Table 2.3). 
 
II G. 3 Major Depressive Episode 
The results of applying successive DSM-IV major depressive episode criterion are shown 
in Table 2.4.  For the NESARC 1.9% (n=864) of the respondents did not provide valid 
(i.e. yes or no) responses to any of the MDE section stem questions.  The criterion 
prevalence estimates are based on those with at least one valid response (n=42,229).  
Remarkably only one respondent to the NCS-R refused themselves out of the MDE 
section.  All three approaches produce similar criterion A and C prevalence estimates 
(Table 2.4) with the NESARC survey-question-based illness and substance induced 
estimates being higher than the NCS-R open form clinician reviewed method.  The 
AUDADIS/NESARC approach identifies 1.6% (n=713) of the population as having 
experienced a MDE that was better explained by bereavement, which representing 8.8% 
(95% CI: 7.9-9.6) of all lifetime MDEs meeting criterion A, C and D.  Comparing the 
AUDADIS/NESARC approach to bereavement with the strict DSM-IV approach shown 
in the AUDADIS/CIDI (DSM-IV) prevalence model shows that very few individuals 
(n=15) are exclude from a MDE due too bereavement.  These represent only 1.7% (95% 
CI: 0.7-2.8) of the 690 that are identified by the bereavement question only approach 
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used in the AUDADIS/NESARC as described above.  These 15 bereaved MDE excluded 
individuals also represent only 0.15% (95% CI: 0.06-0.25) of those meeting MDE 
criterion A, C and D. 
II G. 4 Imputation Analysis 
Table 2.5 summarizes the final prevalence estimates from the reconciled 
AUDADIS/CIDI and NCS-R/CIDI approaches and reports the estimates from the 
imputation analysis.  Little difference is found in the AUDADIS/CIDI estimates for 
mania and hypomania before and after imputation.  The AUDADIS/CIDI MDE estimate 
do not apply criterion E (bereavement) and includes a prevalence estimate of those who 
endorsed depressed mood, anhedonia and a total of five symptoms and skipped out of the 
AUDADIS MDE section (the un-assessed).  The imputation prevalence estimate of this 
group is 75.3% a result consistent with the preliminary estimate of 75%.  The proportion 
of those endorsing depressed mood, anhedonia and a total of five symptoms among those 
endorsing any MDE symptoms was 7.0% (95% CI: 6.5-7.5) for the NESARC and 6.1% 
(95% CI: 5.2-7.1) of the NCS-R.  The remaining NESARC estimates are relatively 
unchanged or decrease slightly in the imputation analysis.  The NCS-R imputation results 
on the other hand show considerable increases in the mania and hypomania prevalence 
estimates and subsequently the bipolar spectrum as a whole.   
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II H. Discussion: 
The successive application of individual DSM-IV manic/hypomanic episode criteria 
demonstrates that a strict adherence to the DSM-IV/CIDI approach within the NESARC 
shifts cases from manic episodes to hypomanic episodes when social/occupational 
impairment criterion is applied.  The bipolar spectrum prevalence, manic or hypomanic 
episodes, remains intact.  Little difference in NESARC bipolar prevalence estimates 
between the pre and post imputation analysis were found.  This suggests that the time 
consuming nature of an imputation analysis is not necessary for bipolar case 
identification in the NESARC.  The prevalence estimate of MDE was significantly 
increased in the imputation analysis though this did not meaningfully impact bipolar II 
estimates.  Substantial difference in NCS-R bipolar prevalence estimates between the pre- 
and post-imputation analysis were found.   
  
The increased imputed prevalence estimates for mania and hypomania in the NCS-R is 
explained by the high proportion (38.5% 95% CI: 34.0-43.0) of those meeting DSM-IV 
manic episode criterion A and B who are precluded from a manic or hypomanic diagnosis 
by failing to be assessed for criterion E, hospitalization or mental health professional 
contact (skipped out at question M9). In addition, of those meeting manic episode 
criterion A and B and endorsing less than a little social or occupational impairment at 
question M9 (n=281), 4.1% (n=13) meet impairment criteria before imputation by way of 
endorsing psychotic features.  Of these 13, 11 meet the recalibration symptom criteria for 
Bipolar I and when these 11 are added to in the Bipolar I prevalence estimate before 
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imputation a prevalence of  1.1% (95% CI: 0.8-1.4) is found.  Imputed hospitalization or 
mental health professional contact is responsible for the bulk of the difference between 
this result (i.e. 1.1%) and the imputed estimate (i.e. 1.3%, Table 2.5).  Imputed 
hospitalization or mental health professional contacts are also primarily responsible for 
the increase in the prevalence estimates of the bipolar spectrum as a whole (4.4% to 
6.4%).   
 
The major structural difference between the two surveys is that for the NESARC those 
endorsing three manic symptom were assessed for all remaining criteria whereas the 
NCS-R skipped-out those who only endorsed less than a little social or occupational 
impairment.  Respondents with true mania may not endorse social or occupational 
impairment due to a lack of insight into the impairing nature of their disorder.  Impaired 
insight has been observed to be greater among bipolar patients with pure manic episodes 
compared to mixed or depressed episodes.76  Particularly relevant to the NCS-R result, 
evidence points to psychotic features in those with bipolar predicting poor insight.77  
Another important difference between the NESARC and the NCS-R is that psychotic 
features were explicitly assessed with a separate question in the NCS-R manic section 
where as the psychotic feature in the NESARC was conflated with grandiosity and for the 
NEASARC/CIDI implementation defined by information collected outside the manic 
diagnostic section (Table 2.1).  Only 18.3% (95% CI: 13.2-23.5) of those meeting Bipolar 
I (pre-imputed re-calibrated) in the NESARC endorse the psychotic feature, as defined, 
where as 37.2% (95% CI: 25.0-49.4) do in the NCS-R (re-calibrated and including the 11 
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cases added in, as above).  Important criterion information on psychotic features in the 
NESARC is clearly lost by the grandiosity and psychotic features being assessed by only 
one question and used as a symptom and not as a symptom and an impairment measure.  
These results demonstrate the dangers of skip-outs in a diagnostic instrument as well as 
the need to independently assess each criterion component individually. 
 
Some limitations on the results merit mention.  The assessment of impairment is difficult 
using self-reports particularly among those experiencing a manic/hypomanic episode.  
The use of census workers, federal government employees, may have limited the 
willingness participates in the NESARC to disclose information about psychiatric 
disorders and substance use (particularly illegal substances including cannabis) compared 
to the NCS-R.  This may have suppressed the prevalence of bipolar disorder particularly 
among those with psychotic features who may have an underlying suspiciousness of 
government.  The elevated mood episode duration of four days assessed by the CIDI may 
not be short enough and is certainly to long, at a week, in the AUDADIS,78 this likely 
suppressed Bipolar II and hypomanic episodes in the NESARC compared to the NCS-R.  
The recalibration algorithm was developed from a small (n=40) sample of those 
endorsing the NCS-R manic section stem questions19 and CIDI case assignment used to 
develop the recalibration algorithm  relied on missing information, as our imputation 
analysis demonstrates.  The SCID, the validating standard of the clinical re-evaluation, is 
itself subject to case misidentification generally.79  More specifically, those more 
appropriately classified as having schizoaffective disorder may have been missed in the 
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clinical re-evaluation as the SCID psychotic screen was not applied.80  Though it should 
be noted that none of the 13 case w/ psychotic features described above were among the 
40 clinical reassessed respondents.81  The assumption that missing criterion information is 
missing at random is reasonable but can not be known and differences in the number of 
available demographic and psychiatric comorbidity variables (i.e. substance use 
disorders) between the surveys may differentially affect the imputation results. 
 
II I. Summary of Findings: 
A strict application of a DSM-IV/CIDI approach to the assessment of impairment within 
the NESARC decreases prevalence estimates of manic episodes and correspondingly 
increases hypomanic episode estimates.  Structural issues with the AUDADIS 
substantially under-estimate the prevalence of lifetime major depressive episode (16.9% 
[95% CI: 16.1-17.6]) compared to imputed estimates that do not conflate anhedonia and 
depressed mood (19.7% [95% CI: 19.3-20.1]).  A skip-out within the CIDI used in the 
NCS-R prevented complete DSM-IV manic and hypomanic criterion information from 
being collected.  Imputation of this missing information resulted in increased prevalence 
estimates for both manic (3.5% [95% CI: 3.1-4.0] increased to 4.4% [95% CI: 3.9-5.0]) 
and hypomanic (1.2% [95% CI: 0.9-1.4] increased to 2.0% [95% CI: 1.6-2.4]) episodes.  
The small differences between the imputed and un-imputed hypomania and bipolar 
prevalence estimates in the NESARC nullify the need to apply imputation for risk 
estimates in later aims. 
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II J. Conclusion: 
The findings of this aim support the conclusion that the AUDADIS substantially under-
estimated lifetime major depressive episode prevalence compared to an imputed estimate 
that treated anhedonia and depressed mood as separate and concurrent MDE symptoms.  
The operationalization of impairment for manic disorders in both the AUDADIS and 
CIDI strongly influences case identification, with the CIDI operationalization suppressing 
manic and hypomanic prevalence estimates.  Skip patterns within the survey instruments 
that violated the DSM-IV criterion structure or logic represent the primary deficiencies 
found.  A practical finding of this aim was that imputed missing information did not 
meaningfully affect bipolar prevalence estimates within the NESARC.    
 
The first aim of this dissertation demonstrated that the operationalization of DSM criteria 
is not always ideally implemented in nationally representative studies.  The consequence 
of this is that psychiatric disorders, specifically manic, hypomanic and major depressive 
episodes, are subject to un-necessary misclassification in these major psychiatric 
epidemiological studies.  Awareness of these shortcomings is needed among the research 
community that represents the consumers of these public use data sets.   
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Chapter III: Cannabis Use and Bipolar Disorder: Cannabis Use Risk Assessment 
 
III A. Aim 
The aim of the research reported in this chapter is to examine cannabis use as a risk factor 
for incident (between NESARC wave 1 and wave 2) manic symptoms, bipolar spectrum 
disorders (DSM-IV mania and hypomania) and CIDI recalibrated BD I and II as defined 
by approaches used in Aim 1.  Cannabis use risk will be assessed in the total population 
and within strata of young adults (ages 18-25), adults (ages 26-45), older adults (ages 
>45) and among those with and without histories alcohol or drug abuse/dependence.  
Examination of risk among those both with and without histories alcohol or substance 
abuse/dependence by developmental age (young adults [ages 18-25] and adults [ages 26-
45]) will be conducted.  Also to be examined are groups that may be at increased risk 
because of baseline sub-threshold symptoms or family history of depression, anti-social 
behavior, alcohol or substance abuse/dependence.  
 
III B. Background 
Longitudinal studies point to cannabis as a risk factor for psychosis. 5, 8, 41, 82-86  A meta-
analysis of cannabis use and psychosis found that individuals having ever used cannabis 
were at increased risk of any psychotic outcomes (pooled adjusted OR: 1.41, 95% CI 
1.20–1.65), and those using cannabis more frequently were at an even greater risk (OR: 
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2.09, 1.54–2.84). 39   Cannabis use is suspected of playing a role in psychosis through 
dopamine dysregulation.40   Cannabis exposure may put carriers of the COMT 
Val(158)Met Val allele, which plays a role in dopamine regulation, at a greater risk of 
psychosis. 41, 42 Dopamine dysregulation is hypothesized to also play an important role in 
BD.87 
 
Recently a family study found that AKT1, which is involved in the phosphorylation of 
glycogen synthase kinase (GSK-3), may mediate psychosis through cannabinoid-
regulated AKT1/GSK-3 signaling downstream of the dopamine D2 receptor.88  The 
clinical presentation of BD often has similar features to the clinical presentation of 
schizophrenia.  Patients with BD often have psychotic symptoms and those with 
schizophrenic disorders often experience mania.43   Twin studies have found genetic 
correlations between schizophrenia and BD. 44   The International Schizophrenia 
Consortium conducted a large genome-wide association study and found evidence for a 
shared polygenic component to the risk of schizophrenia and BD.45  Thus, cannabis 
exposure may increase risk for BD outcomes, possibly thought dopamine dysregulation, 
by acting on the same genetic substrate as it does in psychosis.  
 
However, the limited evidence assessing cannabis use as a risk factor for bipolar disorder 
(BD) provide conflicting results.6-9   A cohort study by van Laar et al,7 found a significant 
association between cannabis and DSMIII-R BD I and II [OR 4.98 (95% CI: 1.80–
13.81)]. The onset definition of this study may have misclassified prevalent BD at 
62 
baseline which may have inflated the risk estimate.  The results of van Laar et al, ,7 are 
consistent, however, with two prospective cohort studies, one also using the NEMESIS 
(Henquet et al), 6 both found significant associations between manic symptoms and 
cannabis use [NEMESIS study OR 2.70 (95% CI: 1.54–4.75)  and the EDSP study, OR 
4.26 (95% CI: 1.42–12.76)9 ].  The manic symptom outcomes in the Henquet et al 
NEMESIS study had a low symptom duration threshold with respondents needing to only 
endorse one symptom persisting for 2 days (their operationalization of DSM-III-R 
criteria) to be positive.  The EDSP study had a small sample size with only six cannabis 
exposed cases, raising questions about statistical power and violations of the assumption 
of parallel regression in their four level ordinal logistic regression model.   The results 
from the NEMESIS and EDSP studies conflict with a result from the Swedish Conscript 
Cohort (n=50,087) which found a null association [OR 1.13 (95% CI: 0.82 to 1.57)] 
between cannabis use by age 18 and future affective psychosis hospitalization 
(predominately BD diagnoses).8, 10  The conflicting results are likely partially explained 
by the more severe outcome (hospitalization) in the Swedish Conscript Cohort compared 
to the symptom level and the not-necessarily-hospitalized DSM-III-R BD I and II 
outcomes of the NEMESIS and EDSP studies.  No study to date has assessed cannabis 
use as a risk factor for DSM-IV BD with a sample as large as the NESARC, nor has any 
study examined risk among those with no reported lifetime manic or major depressive 
symptoms at baseline. 
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Cannabis abuse has been associated with earlier onset of schizophrenia with the 
interpretation that cannabis use precipitates or accelerates the onset in those at risk.46, 47  
In BD a similar observation has been made whereby onset after a substance use disorder, 
cannabis or alcohol, has been hypothesized to be an added insult, or diathesis, that may 
manifests BD.48, 49   To examine whether cannabis use status imparts different risk among 
those with histories of substance abuse/dependence and those without such histories, a 
stratified analysis will be used.   Examining cannabis exposure risk within groups defined 
by age and substance abuse/dependence status may provide evidence from a population 
sample that supports the diathesis hypothesis. 
 
III C. Methods 
III C. 1 Sample 
The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) is 
the largest national epidemiologic survey to date to assess for a wide range of mental 
illnesses and co-occurring mental health and substance use disorders using the Diagnostic 
and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV). The survey was 
conducted in two waves (2001-2002 and 2004-2005) of face-to-face interviews with non-
institutionalized respondents, including those living in dormitories, boarding houses, 
shelters, and off-base military housing (Chen et al, 2006); prisons, jails and hospitals 
were not sampled. Both waves are adjusted to be representative of the adult non-
institutionalized U.S. population (18 years of age and older) (Grant et al, 2003; Grant et 
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al, 2004), wave 1 had a response rate of 81.2% (n= 43,093)23, 24 and wave 2 (n= 34,653) 
had a cumulative response rate of 70.2%.25   
 
III C. 2 Diagnostic Measures 
The Alcohol Use Disorder and Associated Disabilities Interview Schedule–DSM-IV 
Version (AUDADIS),28  a structured diagnostic interview designed for use by lay 
interviewers, was administered at wave 1 to determine lifetime and recent (past 12 
months) diagnoses of major Axis I and Axis II disorders, including dysthymia, bipolar 
disorder, anxiety disorders (agoraphobia, panic disorder, social phobia, specific phobia 
and generalized anxiety disorder), antisocial personality disorder (ASPD), conduct 
disorder (with no subsequent ASPD), other personality disorders (paranoid, schizoid, 
avoidant, dependent, obsessive–compulsive and histrionic), and substance abuse or 
dependence (including alcohol, marijuana, cocaine, opioids, hallucinogens, 
methamphetamine, or other illicit drugs).  A modified version of the AUDADIS for the 
assessment of DSM-IV disorders within the intervening 3-years period between wave 1 
and wave 2 was used to identify incident bipolar spectrum outcomes.  This same wave 2 
interview assessed, adverse events, post traumatic stress disorder (PSTD) and childhood 
attention deficit hyperactivity disorder (ADHD).  The three primary outcomes of this 
study are incident manic symptoms, incident bipolar spectrum disorders (DSM-IV manic 
and hypomanic episodes) and CIDI recalibrated BD I and II outcomes.  Incident 
manic/hypomanic symptoms were defined as the endorsement of any stem questions in 
the manic/hypomanic sections of the AUDADIS, which involved the endorsement of a 
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week or more of extremely elevated or irritable mood.  The diagnostic operationalization 
of manic and hypomanic episodes in both wave 1 and wave 2 in this cannabis use risk 
analysis conform to the NESARC/CIDI approach (w/no imputation) defined in Aim 1 
(Chapter 2).  The primary difference between manic and hypomanic episodes case 
identification in this analysis and those reported by the NESARC investigators is how 
social and occupational impairment are operationalized (manic episode criterion D and 
hypomanic episode criterion E, see Aim1 for details).  The diagnostic operationalization 
of CIDI recalibrated BD I and II outcomes are described in detail in Aim 1.  Lifetime 
DSM-IV disorders at wave 1 and collected in the wave 1 interview were coded for use in 
multivariate models as potential confounders of the association of cannabis and BD.  
Most of these disorders have been reported to be associated with both cannabis use and 
BD.16, 50  The DSM-IV diagnostic measures used in this analysis include:  alcohol abuse, 
alcohol dependence, nicotine (tobacco) dependence, other drug (sedatives, tranquilizers, 
cocaine, opioids, hallucinogens, amphetamine, inhalants, heroin or other drugs used 
without a prescription) abuse and a separate indictor for other drug dependence, lifetime 
dysthymia, agoraphobia or panic disorder, social phobia, specific phobia, generalized 
anxiety disorder (GAD), conduct disorder (with no ASPD), ASPD, and other personality 
disorders as delineated above.  Post traumatic stress disorder (PTSD) and childhood (<18 
years of age) attention deficit-hyperactivity disorder (ADHD) were assessed at wave 2 
interview for disorder onset before the wave 1 interview.  DSM-IV disorders were 
dichotomously coded (0= not endorsed, 1= endorsed) with respondents being coded as 
missing if they failed to either positively or negatively endorse all the stem questions 
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from the corresponding disorder’s diagnostic section in the AUDADIS.  Aggregated 
dichotomous indicators of the presents of any substance use disorder and any non-
substance use psychiatric comorbidity were created for use in the analysis of lower count 
strata.  
 
III C. 3 Exposure Measures 
Cannabis use was coded in several ways.  Ever having used cannabis (ever used), lifetime 
use prior to past year (distal use) and use within past year at wave 1 (proximal use) were 
dichotomously coded (0= not endorsed, 1= endorsed).  To assess a dose response, 
cannabis use was further categorized into five use groups (no reported use, >=1 use/week 
in the last 12 months, <1 use/week in the last 12 months, >=1 use/week before the last 12 
months, and <1 use/week before the last 12 months).  All cannabis exposures were 
assessed at the wave 1 (baseline) interview and represents cannabis use within one year 
of the baseline interview or any time prior to the past years of the baseline interview.  
Those not positively or negatively endorsing ever using cannabis are coded as missing. 
 
III C. 4 Family History Score 
Alcohol and substance abuse are highly comorbid with BD 51    and alcohol abuse and 
BD aggregate in families.52   Evidence suggests substance use disorders, depression and 
antisocial traits are concentrated in families of those with early-onset BD.53  To capture 
potential familial/genetic risk for BD a proxy measure was constructed, a family history 
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density score. The family history density score represents the density89 of first-degree 
relatives (parents, full brothers and sisters, sons and daughters) identified by the 
respondent as experiencing either major depression, alcohol abuse, substance abuse, or 
anti-social behavior.  The crude family history density score is constructed by counting 
all reported major depression, alcohol abuse, substance abuse, and anti-social behavior 
among the respondents first-degree relatives and dividing this by four and then by the 
number of first-degree relatives.  The score can range from 0 to 1.  A score of 1 means all 
first degree relative reported being positive for all four traits (alcohol abuse, depression, 
substance abuse and antisocial behaviors) with lower scores representing decreasing 
concentration of these traits.  The non-zero crude family history density scores have a 
log-normal distribution.  A three level categorical variable was created from the crude 
family history density scores: family history density score=1 if the crude score equaled 
zero, family history density score=2 for those in the lowest median of those with non-
zero densities (mean 0.058, median 0.063, range 0.008 – 0.1) and family history density 
score=3 for those in the highest median of those with non-zero densities (mean 0.241, 
median 0.2, range 0.102 – 1.0). 
 
III C. 5 Other Measures 
A history of traumatic events early in life (e.g.. abuse, neglect) has been associated with 
later major depression, psychosis and substance abuse.90, 91  A dichotomous indicator of 
early life adverse events was coded as positive if the respondent endorsed experiencing 
any of the following before age 13: being in a war zone, being a refugee, experiencing a 
68 
life threatening illness, natural disaster, molested, abused, neglected, were in physical 
fights, injured in a fight, kidnapped, stalked, mugged, yourself or someone close to you 
directly effected by terrorism, unexpectedly witness severe injury/killing/dead body, 
someone very close with life threatening illness/injury or traumatic event, or other 
traumatic event.  Other substance use (sedatives, tranquilizers, cocaine, opioids, 
hallucinogens, amphetamine, inhalants, heroin or other drugs used without a prescription) 
was coded to a dichotomous indicator (0= not endorsed, 1= endorsed).  Respondents 
endorsing lifetime use of cigarettes <100 times, cigars or pipes <50 times and the use of 
oral tobacco products <20 times were coded as no/low tobacco users (0=not no/low users, 
1= no/low users).  Baseline norms based mental health score from the Short Form-12 
version 2 (SF-12v2)92 were categorized into quartiles (Table 2.2) with increasing 
quartiles associated with increasing norms based mental health. 
 
III C. 6 Demographic Measures 
Demographic measures included: gender (male=1, female=0), age cohort (1= 18 to 25, 
2=26 to 35, 3=36 to 45, and 4 =46 and older), self reported race/ethnicity (white=1, 
black=2, Hispanic or Latino=3, American Indian/Alaska native=4, and 
Asian/Hawaiian/Pacific Islander=5) for the sub-group analyses race/ethnicity groups 4 
and 5 were collapsed into one group, personal income ($) quartiles (1= <=8800, 2= 8801 
to <= 20000, 3= 20001 to <=36000, 4= >=36001), education status (1= < high school, 
2=high school or GED, 3= some college or an Associate Degree, 4= >= Bachelor’s 
Degree), urbanicity (1= urban, in central city of Metropolitan Statistical Area [MSA], 
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2=suburban, in MSA but not in central city, 3= rural, not in a MSA), census region (1= 
Northwest, 2= Midwest, 3= South, 4= West), and marital status (1=married or living with 
someone as if married, 2= divorced or separated, 3= widowed, 4= never married). 
 
III D. Data Analysis 
The demographic characteristics (counts, weighted means) of the cohort as a whole and 
by cannabis use status will be reported.  Descriptive statistics (counts, proportions) and 
measures of association (odds ratios) of baseline covariates with ever reporting using 
cannabis in the wave 1 interview and incident bipolar spectrum disorders will also be 
reported.  Separate logistic regression models were constructed to assess cannabis use as 
a risk factor for incident manic symptoms, DSM-IV bipolar spectrum outcomes as well as 
for the more strictly defined CIDI recalibrated BD I and II outcomes.  The onset of 
bipolar outcomes was defined for the primary analysis as the age at which the first 
bipolar symptoms (DSM-IV manic, hypomanic or MDE symptoms) were reported.  To 
avoid including prevalent emergent BD in our analytical cohort respondents reporting 
manic, hypomanic or MDE symptoms at baseline were excluded from the primary 
analysis.  Subsequent stratified analyses include those with manic, hypomanic or MDE 
symptoms at baseline but control for the presents of these symptoms.  All analysis 
excluded any respondents who reported at wave 1 ever having a medical professional say 
they had schizophrenia or a psychotic illness or episode. With the exception of counts all 
reported statistics are probability weighted to be representative of the U.S. population. 
Variances were estimated by Taylor series linearization with single primary sampling 
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unit strata centered at the overall mean. All of the analyses were performed using STATA 
statistical software.93   
 
III D. 1 Nested Models 
The primary analysis consist of a series of nested logistic regression models that assess 
cannabis use as a risk factor in the population as a whole for three incident manic episode 
related outcomes; any manic symptoms, bipolar spectrum disorders and CIDI recalibrated 
BD I and II.  The first model (Model 1) assesses the association of ever using cannabis 
and incident BD outcomes, the second model (Model 2) stratifies ever use into proximal 
(within past year of baseline interview) and distal use (prior to past year use).  The third 
model (Model 3) added demographic factors to Model 2 to adjust risk estimates by age, 
gender, race/ethnicity, education level, marital status, urbanicity and region.  It should be 
noted that urbanicity may modify cannabis use risk for psychosis94 and geographical 
region,95 specifically increasing latitude, has been associated with increased risk for 
schizophrenia.  Thus, urbanicity and region maybe risk factors for bipolar disorder.  
Model 4 adds histories of substance use disorders (alcohol, cannabis, other drugs and 
nicotine), other illicit drug use and smoking to Model 3 to control for potential 
confounding of cannabis use with other substance use.   
  
Model 3:   logit(p)=ln{p/(1-p)}= β0 + β1proximal cannabis +  β2distal cannabis + [β3gender+  β4age +… 
+  βiwest region ] 
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Model 5 added the family history density score and childhood adverse events to Model 4 
to control for possible genetic or environmental exposures associated with these 
measures.  The final model (Model 6) added indicators for lifetime and baseline mental 
health at wave 1: SF-12v2 mental health norm-based score and baseline history of 
psychiatric comorbidities including dysthymia, PTSD, agoraphobia or panic disorder, 
social phobia, specific phobia, generalized anxiety disorder (GAD), conduct disorder 
with out antisocial personality disorder (ASPD), ASPD, childhood attention deficit 
hyperactivity disorder (ADHD) and other personality disorders (avoidant, dependent, 
obsessive-compulsive, paranoid, schizoid and histrionic).  The psychiatric comorbidity 
measures in Model 6 and the family history density score and childhood adversity 
measures in Model 5 represent or are proxies for possible underlying factors that may 
cause both bipolar disorder and cannabis use. Covariate dichotomous and categorical 
variables are only included in any of the models if they have a minimum cell count of 3.  
The collinearity of covariates in all reported models was examined by assessing the 
variance inflation factor (VIF) of a weighted linear regression model of the dependent 
variable using all the independent variables.  A VIF of 10 or greater is indicative of 
collinearity.  No covariates with a VIF of >5 are included in any of the models.  The 
variables for each of the nested models are added as a group as described. 
 
III D. 2 Symptom Threshold Analysis 
To assess cannabis use risk for sub-bipolar spectrum disorder outcomes of increasing 
symptom concentration, three models with outcomes with an increasing number of manic 
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episode criterion B symptoms were constructed. The three outcomes assessed were all 
among those reporting no manic, hypomanic or MDE symptoms at wave 1 and represent 
incident events between the wave1 and wave 2 interviews.  The sub-bipolar spectrum 
disorder outcomes all included a week or more of incident elevated or irritable mood and 
were defined as follows: 1) at least 1 incident criterion B symptom (n=1009), 2) 2 or 
more incident criterion B symptoms (n=771), and 3) at least 3 criterion B symptoms 
(n=532).  All the covariates described above were included in the adjusted models of all 
three outcomes. 
 
III D. 3 Lifetime Manic/Hypomanic or MDE Symptoms at Baseline 
Respondents with any lifetime manic or MDE symptoms at baseline, the population 
excluded from the primary nested model analysis, were analyzed as a separate strata for 
bipolar spectrum disorder and CIDI recalibrated BD I and II outcomes.  The model of 
incident bipolar spectrum disorders excluded those meeting lifetime criteria for bipolar 
spectrum disorders (DSM-IV manic and hypomanic episodes) at wave 1.  The model of 
incident CIDI recalibrated BD I and II excluded those meeting lifetime criteria CIDI 
recalibrated BD I and II at wave 1.  All the covariates described above were included in 
the adjusted model of bipolar spectrum outcomes with the model of CIDI recalibrated BD 
I and II including adjustment for any (non- CIDI recalibrated BD I and II) lifetime 
bipolar spectrum disorders at baseline. 
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III D. 4 Sub-group Analyses 
Sub-group analyses were conducted within populations stratified by age cohort, family 
history score groups, substance abuse/dependence status and within strata stratified by 
substance abuse/dependence status and age cohort.  With the exception of the age cohort 
analysis all the subgroup analyses were restricted to respondents aged 18 to 45.  This 
restriction was done so that there would be increased power to detect an effect between 
proximal cannabis use and incident bipolar spectrum outcomes as older respondents 
report current cannabis use infrequently.  These analyses may provide evidence for effect 
modification across these domains.   
 
III D. 5 Age Cohorts 
The association of cannabis use (specified as a five level or three level exposure variable) 
with incident bipolar spectrum disorders by age cohorts (ages 18 to 25, 26 to 45, and 46 
and older) was assessed.  For this analysis those with lifetime baseline manic/hypomanic 
or MDE symptoms but not meeting criteria for a DSM-IV manic or hypomanic episode 
were included.  A dichotomous indicator of the presents of any lifetime baseline 
manic/hypomanic or MDE symptoms (0= no symptoms, 1= symptoms) was created and 
included in adjusted models along with the other covariates included in the primary 
nested bipolar spectrum disorder model (Model 6).  The number of covariates included in 
a logistic regression model can be relatively large (< 4 events per predictor variable) with 
little bias particularly if the sample size is large, sparse cell sizes are addressed, 
74 
collinearity is minimal and the goal of the analysis is the assessment of potential 
confounding.96 
 
III D. 6 Family History Strata 
The examination of proximal and distal cannabis use as a risk factor for bipolar spectrum 
disorders and CIDI recalibrated BD I and II across strata defined by family history score 
groups was conducted.  Separate models for both the bipolar outcomes were evaluated for 
each of the three family history score groups: 1) among those reporting no family history, 
2) among those in the lowest family history score median, and 3) those in the highest 
family history score median.  The logistic regression models included all of the covariates 
described above with the exception that aggregated substance abuse/dependence and 
psychiatric comorbidity indicators were used.  The proportion of incident BD outcomes 
within each stratum will also be reported.  
 
III D. 7 Substance Abuse or Dependence Strata 
Two substance abuse or dependence strata were defined: those endorsing any lifetime 
substance abuse/dependence (alcohol, cannabis or other drugs) or having nicotine 
dependence at wave 1 and those not endorsing any such abuse or dependence.  The odds 
of incident DSM-IV manic or hypomanic events among those reporting proximal and 
distal cannabis use was assessed within these substance abuse or dependence strata.  To 
assess whether developmental stage influences risk, both substance abuse/dependence 
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stratum were further stratified by age (18 to 25 years of age [young adults], and 26 to 45 
[adults]) and cannabis use risk was likewise assessed with in these (four) groups.  A dose 
response analysis using the five level cannabis use measure was done among the lifetime 
substance abuse/dependence strata by age. 
 
III E. Results 
The demographic characteristics of the cohort are shown in Table 3.1.  Table 3.2 reports 
the counts and proportions of substance use, substance use disorders, psychiatric 
comorbidities, and other measures and their association with ever having used cannabis 
and incident DSM-IV manic or hypomanic episodes.  Only respondents reporting no 
lifetime manic or MDE symptoms at wave 1 are included in Table 3.2.  This exclusion of 
those with manic or MDE symptoms for the primary nested model analysis, the analytical 
population on which Table 3.2 reports, leaves some covariates with relatively low 
representation (i.e. other drug dependence and dysthymia).  Separating those with only 
conduct disorder from those with ASPD (which requires both a history of conduct 
disorder and adult ASPD) also finds those reporting only conduct disorder with relatively 
low representation. Most of these covariates and/or potential confounders are both 
positively (odds ratios greater than 1) and significantly associated with both cannabis use 
and incident bipolar spectrum outcomes. Notably alcohol abuse only (not including those 
with dependence) is crudely associated with reduced risk for manic or hypomanic 
outcomes whereas alcohol dependence is associated with increased risk.  Increasing 
family history scores are associated with increasing likelihood of reporting ever using  
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cannabis.  Respondents in the highest median, but not those in the lowest median, of the 
family history score are at increased risk for bipolar spectrum outcomes compared to 
those reporting no family history. 
III E. 1 Nested Models 
Table 3.3 reports the result of the primary nested model analysis for incident manic 
symptoms and incident DSM-IV manic and hypomanic episodes.  Table 3.3 (cont.) 
reports the result of the nested model analysis for incident CIDI recalibrated BD I and II 
episodes.  Models of all three outcomes find statistically significant (p<.05) un-adjusted 
risk concentrated in past year cannabis use (proximal use, Model B).  The odds of 
incident manic symptoms associated with proximal cannabis use is attenuated slightly by 
the adjustment for other substance use and substance use disorders but remains 
significant in the fully adjusted model (Model F, OR 1.67, 95% CI: 1.12-2.48, p=.01).  
For incident bipolar spectrum disorders proximal use, but not distal use, remained 
significant after control for demographic characteristics but no longer remained 
significant after adjustment for other substance use and substance use disorders (Table 
3.3).  Like incident bipolar spectrum disorders the CIDI recalibrated BD I and II 
outcomes saw proximal use, but not distal use, remained significant after control for 
demographic characteristics but no longer remained significant after adjustment for other 
substance use and substance use disorders [Table 3.3 (cont.)]. 
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III E. 2 Symptom Threshold Analysis 
The results of the symptom threshold analysis are found in Table 3.4.  For all respondents 
with no lifetime manic or MDE symptoms at wave 1 past year cannabis use, but not use 
prior to the past year, is associated with increased odds of an incident week of extremely  
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elevated or irritable mood accompanied by at least one manic episode criterion B 
symptom (adjusted OR 1.94, 95% CI: 1.29-2.93, p=.002).  Past year use of cannabis was 
also associated with increased odds of an incident week of extremely elevated or irritable 
mood accompanied by at least two manic episode criterion B symptoms (adjusted OR 
1.69, 95% CI: 1.08-2.65, p=.02).  Proximal cannabis use was not however significantly 
associated with an incident week of extremely elevated or irritable accompanied by at 
least three manic episode criterion B symptoms (adjusted OR 1.33, 95% CI: 0.75-2.36, 
p=.32). 
III E. 3 Lifetime Manic/Hypomanic or MDE Symptoms at Baseline 
Table 3.5 reports the odds of incident manic outcomes, DSM-IV manic and hypomanic 
episodes and CIDI recalibrated BD I and II, with proximal and distal cannabis use and 
with cannabis use categorized into five-levels.  Among those reporting any manic or 
MDE symptoms at baseline cannabis use is not a significant risk factor for incident manic 
outcomes (Table 3.5). 
 
III E. 4 Results from Sub-group Analyses: Age Cohorts 
Table 3.6 reports the adjusted associations of cannabis exposure with incident bipolar 
spectrum disorders by age cohorts (ages 18 to 25, 26 to 45, and >46).  Compared to those 
reporting never using cannabis no level of cannabis use was associated with incident 
bipolar spectrum disorders among the young adults (Table 3.6).  Among adults (ages 26 
to 45) >=1 use of cannabis per week was associated with incident bipolar spectrum 
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disorders (adjusted OR 2.52, 95% CI: 1.32-4.80, p=.006).  Curiously members of the 
same age cohort reporting historic low levels of cannabis use (< 1 use per week before 
last 12 months at baseline) also experience significantly increased risk of incident bipolar 
spectrum outcomes (adjusted OR 1.47, 95% CI: 1.01-2.12, p=.05).  Low numbers of  
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incident bipolar spectrum disorder and reported uses of cannabis >=1 use of per week 
restricted cannabis use risk assessment among those older than 46 years of age to past 
year and prior to past year use.  For the older adults both proximal and distal use had 
odds ratios for incident bipolar spectrum disorders of less than one. 
III E. 5 Family History Score Strata 
The analysis of cannabis use risk by family history score strata is reported in Table 3.7.  
Respondents reporting no alcohol or substance abuse or dependency, major depression or 
anti-social traits in their first degree relatives are at increased risk for incident bipolar 
spectrum disorders (adjusted OR 2.27, 95% CI: 1.01-5.10, p=.05) and CIDI recalibrated 
BD I and II (adjusted OR 5.49, 95% CI: 1.38-21.9, p=.02) if they endorsed proximal 
cannabis use.  Respondents reporting family history traits such that they entered into the 
lowest median of those with any positive family history reports were at non-significant 
reduced risk for incident bipolar outcomes for both proximal and distal cannabis use 
endorsement (Table 3.7).  Cannabis use is not significantly associated with incident 
outcomes among those respondents in the highest median of those with any positive 
family history reports. 
 
III E. 6 Substance Abuse or Dependence Strata 
The association of past year and prior to past year cannabis use and incident manic or 
hypomanic episodes among those with and without a history of substance abuse or 
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dependence (nicotine dependence or alcohol, cannabis or other substance abuse or 
dependence) are reported in Table 3.8A.  Neither proximal nor distal cannabis use are not 
significantly associated with bipolar spectrum disorder outcomes in either group.  Table 
3.8B shows risk estimates for those with and without substance abuse or dependence 
stratified into young adult (18 to 25 years of age) and adult (26 to 45 years of age) 
cohorts.  Proximal cannabis use risk in those with substance abuse/dependence histories 
is concentrated in those aged 26 to 45 (adjusted OR 2.00, 95% CI: 1.10-3.66, p=.02) with 
a null result for the young adult cohort with substance abuse/dependence histories 
(adjusted OR 1.13, 95% CI: 0.49-2.61, p=.77).  Cannabis use prior to the past year  
is not associated with incident manic or hypomanic episodes among both age cohorts  
with substance abuse/dependence histories.  Both proximal and distal cannabis use are 
not significantly associated with bipolar spectrum disorder outcomes among both young 
adults and adults without a history of substance abuse/dependence.  Table 3.8C reports 
cannabis use risk across the five-level exposure categories among the adults with 
substance abuse/dependence histories.  Limited power (low cell counts) among the other 
substance abuse/dependence age cohort sub-strata groups restricted the analysis of 
cannabis use risk across the five-level exposure categories to the adults (26 to 45 years of 
age) with substance abuse/dependence histories.  Those with substance abuse/dependence 
at baseline and reported the highest level of cannabis use (>= 1 use per week) at baseline 
are at significantly increased adjusted risk of incident bipolar spectrum outcomes at wave 
2 (adjusted OR 2.52, 95% CI: 1.22-5.21, p=.01).  This high cannabis use group is also at 
an elevated though not statistically significant risk for the CIDI recalibrated BD I and II  
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outcomes (adjusted OR 2.39, 95% CI: 0.87-6.62, p=.09).  The other cannabis exposure 
groups do not have significant associations with incident bipolar outcomes (Table 3.8C). 
III F. Comments 
The strong association of the listed potential confounders in Table 3.2 with both cannabis 
use and incident bipolar spectrum disorders is considerable.  The accumulative effect of 
these covariates is seen in the comparison of the corresponding Model C with Model F in 
the three series of nested models of Table 3.3.  The percent change in the proximal 
cannabis use coefficient (standardized for a unit variance in the independent and 
dependent variables) between Model C with Model F in the incident manic symptom 
models was 34%, 56% for the incident bipolar spectrum disorder series, and 69% for the 
CIDI recalibrated series.  Proximal cannabis remained a significant risk factor for 
incident manic symptom but not for bipolar spectrum disorders.  Collectively other 
substance use (abuse/dependence), childhood factors, family history, and preexisting 
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psychiatric liability explain a substantial portion of the association between past year 
cannabis use and incident bipolar spectrum disorder outcomes.  Though care was made to 
include all relevant potential confounding factors the possibility that uncontrolled 
confounding exists can not be dismissed and the large percentage changes in effect 
estimates coefficients only underscore this point.  Specifically uncontrolled confounding 
in the form of unmeasured genetic predisposition for both cannabis use and bipolar 
spectrum disorders that is not captured in the family history score groups can not be ruled 
out.    
 
The risk estimates reported in Table 3.3 are for events over a relatively short three year 
period among those with no lifetime manic or major depressive episode symptoms at 
baseline.  The power to detect increased risk in this relatively low risk population 
(incident manic or hypomanic episodes 1.9%, 95% CI: 1.7- 2.2) may be limited.  The 
symptom threshold analysis (Table 3.4) provides evidence that proximal cannabis use is 
associated with incident sub-DSM-IV disorder level manic outcomes, specifically for 
manic symptom events featuring a week or more of extremely elevated or irritable mood 
with two or more manic episode criterion B symptoms.  This result should be interpreted 
with some caution as only respondents endorsing three or more manic episode criterion B 
symptoms were asked whether their episode was substance induced or not.  Indeed all of 
the symptom level estimates do not exclude substance induced events unlike the disorder 
level outcomes (manic and hypomanic episode, CIDI recalibrated BD I and II).  Among 
those with two or more manic episode criterion B symptoms in the analysis reported in 
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Table 3.4 (n=768) n=50 report proximal cannabis use.  These proximal cannabis users 
were more likely (OR 1.87, 95% CI: 0.97-3.64, p=.06) to report racing thoughts or 
finding it hard to follow their own thoughts as compared to the non-proximal cannabis 
users, suggesting the possible role of cannabis’s acute psychotropic effects. 
 
Unlike the population assessed in the primary nested model analyses the cohort with 
lifetime manic or major depressive episode symptoms at wave 1 were at relatively high 
risk.  The cohort with lifetime manic or major depressive episode symptoms at baseline 
experienced 5.1% (95% CI: 4.6-5.7) incident manic or hypomanic episodes over the three 
year follow-up period (Table 3.5).  Reported cannabis use was not associated with bipolar 
spectrum disorders in this at-risk population.  This result does not support an interaction 
between depressive or manic symptoms and cannabis use.  Even among those age 18 to 
45 with manic symptoms at baseline (n=1471), who are at very high risk with 11.7% 
(95% CI: 9.5-13.9) experiencing incident manic or hypomanic episodes between wave 1 
and wave 2, are not at significantly higher risk because of proximal cannabis use (OR 
1.64, 95% CI: 0.87-3.09, p=.12, age group and gender adjusted).  Similar results were 
seen among those with major depressive episode symptom (results not shown).  These 
results suggest the possibility that the pathway in which cannabis may confer risk is 
‘already in use’ or has reached a threshold in these symptomatic respondents such that the 
effect of an additional cannabis ‘insult’ is limited if present at all. 
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The age cohort sub-group analysis is informative in that we see that the older adult cohort 
is at reduced risk for incident outcomes related to reported cannabis use status (Table 
3.6).  This result is not so surprising in that this older group includes those that have been 
selected based on their long history of not experiencing a manic or hypomanic episode 
while being exposed to cannabis, i.e. if cannabis exposure does have an adverse effect it 
would have likely already removed at-risk individuals from the risk pool.  The result that 
adults (26 to 45 years of age) but not young adults (18 to 25 years of age) are at increased 
risk from proximal cannabis use may point to developmental differences, greater 
accumulative exposure in the 26 to 45 year olds or other characteristics of this age group 
such as substance abuse and dependence (discussed later) that maybe driving risk.  It 
should be noted that the increased risk in those 26 to 45 years of age using cannabis at the 
highest use level remained when those with symptoms of mania and major depression 
were excluded (adj. OR 2.82, 95% CI: 1.12 – 7.07, p=.03).  The increased, though not 
necessarily significant, risk across all exposure groups for the 26 to 45 year olds suggest 
that prior to past year use is also be a risk factor in this age group.  The significant odds 
of incident bipolar spectrum disorders among those reporting <1 use per week prior to the 
past 12 month could also be the result of under-reporting of current use, where 
respondent may feel more comfortable reporting prior to past year use while actually 
being a current user. 
 
The results from the family history score stratified analysis offer challenges for 
interpretation (Table 3.7).  Characteristic of the family history score itself likely 
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contribute to the divergent risk estimates between those with no reported family history 
and those in the lowest median of those with family history reports.  Increasing age (OR 
1.04, 95% CI: 1.03-1.04, p<.0001) and increasing family size (OR 1.15, 95% CI: 1.13-
1.18, p<.0001) are strongly associated with inclusion in the lowest median family history 
group compared to the no reported history group.  Being older and having a larger family 
increase the time and number of people at risk for the traits the family history score 
captures, increasing the likelihood of inclusion.  Both age (OR 0.92, 95% CI: 0.91-0.93, 
p<.0001) and family size (OR 0.82, 95% CI: 0.79- 0.86, p<.0001) are also associated 
with a reduced risk of proximal cannabis use.  One interpretation of the results for the 
first two family history strata is that the process of creating the no versus low family 
history groups preferentially placed older high-risk non-cannabis using respondents into 
the lowest median family history group as opposed to the no family history group, 
possibly lowering risk estimate in the former and increasing them in the latter group.  In a 
post hoc analysis a group defined by combining the no reported family history group with 
the lowest median group finds proximal cannabis use is no longer a significantly 
associated with incident bipolar spectrum disorders (OR 1.27, 95% CI: 0.65 – 2.49, 
p=.48) or CIDI recalibrated BD I and II (OR 1.38, 95% CI: 0.40 – 4.77, p=.60).  An 
alternative interpretation of the elevated risk in the no reported history group is that the 
environmental exposures like cannabis maybe more easily detected in a group with low 
inherent risk and the risk estimates are unbiased.  In the present analysis it is not possible 
to disentangle the family history scores identification of a low risk population (no 
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reported history) from its possible selection effects (selection of higher risk non-proximal 
cannabis using respondents out of the no reported family history group).   
 
 
Evidence that certain age groups with substance abuse or dependence are at increased 
risk from cannabis exposure is found in these data (Table 3.8B).  The result that risk for 
bipolar spectrum disorders among those with a history of substance abuse or dependence 
is concentrated in those aged 26 to 45 (Table 3.8B, 3.8C) is consistent with observations 
in other bipolar cohorts.48, 49  The result does not constitute a significant multiplicative 
interaction however (interaction p=0.25) and represents a modest increase in risk.   In 
these other bipolar cohorts alcohol or cannabis dependence over an extended period 
preceded a bipolar onset.  Cannabis exposure may function as a component cause of 
mania and increase risk among those with a substance abuse/dependence history, 
particularly among those with longer histories of abuse/dependence, such as is likely the 
case in our 26 to 45 year old cohort.  Excluding those with cannabis abuse or dependence 
from the significant risk estimate in reported in Table 3.8B saw only marginally changes 
in the effect estimates for the high use group (OR 1 .89; 95%  CI : 1.07 – 3.34, p=.03) 
suggesting cannabis use, not raising to the level of abuse or dependence, is driving risk in 
this population. 
 
An important feature of the NESARC cohort is the relatively low reported prevalence of 
lifetime cannabis use.  Nationally representative prevalence estimates published by the 
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National Institute on Drug Abuse (NIDA) point to considerably higher cannabis use rates 
then seen in the NESARC for the year 2001, with 18 to 28 year olds reporting past years 
use at 29.2% and lifetime use at 55.7%.97   Grucza et al 54 compared substance use and 
substance use disorder prevalence estimates between the NESARC and the 2002 National 
Survey on Drug Use and Health (NSDUH). The NSDUH found lifetime and past year 
cannabis use prevalence estimates to be 2.1 and 2.6 times those reported in the NESARC 
respectively but with no significant difference between the surveys for past year cannabis 
use disorders (p=.32). 54  The association of ever using cannabis and the use of other 
drugs with bipolar spectrum disorders reported in Table 2.2 may be inflated as the 
suppression of substance use reporting in the NESARC was disproportionately among 
those not reporting poly-substance use.54  All illicit substance use prevalence estimates 
are lower in the NESARC as compared to the NSDUH.    Grucza et al suggest that the 
use of computerized self-administration methods (ACASI) by the NSDUH, which allows 
respondents to anonymous enter sensitive information, may in part account for the 
differences in the prevalence estimates.  The NESARC, by contrast, collected information 
in a face to face interview using census worker, federal employees, which may have 
suppressed reports of illegal substance use.  Misclassification of cannabis use most 
certainly exists in the NESARC data.  If the suppression of self-reported cannabis use in 
the NESARC is uniform (with false positive rates approximately null), and 
misclassification is non-differential with respect to incident manic outcome status, effect 
estimates will be biased toward the null assuming classification is independent of other 
errors.98  The possibility of differential misclassification exists particularly if those with 
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greater underlying risk (i.e. poly-substance users, more comorbid disorders, etc.) 
preferential report cannabis use.  Aim 3 of this dissertation is a sensitivity analysis that 
uses external predicted probabilities of cannabis exposure from the National Comorbidity 
Survey Replication to assess the influence of hypothetically un-suppressed cannabis use 
reporting on risk estimates. 
 
III G. Limitations 
Certain limitation of the research reported above need to be acknowledged.   As 
previously discussed the self-reported exposure of this study is of an illegal substance.  
There is likely misclassification of exposure which may undermine the validity of the risk 
estimates.  The likely suppression of reports of other illicit substance use may have 
limited the adequate control of confounding.  The proxy measures of underlying genetic 
risk and childhood histories (i.e. family history scores and childhood adverse events) are 
likely weak proxies, leaving open the possibility of uncontrolled confounding via 
inadequate or unmeasured underlying risk.   The NESARC sample does not include 
institutional settings which likely disproportionately include cannabis exposed 
individuals on the bipolar spectrum, potentially biasing estimates toward the null.  The 
statistical power of some of the analyses was low.  Collectively these limitations need to 
be considered when interpreting the risk estimates. 
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III H. Strengths 
In spite of the noted limitations this study has some important strengths. This study used 
the largest longitudinal nationally representative sample available.  The large sample size 
allowed the assessment of cannabis use risk within the population as a whole and in sub-
populations defined by symptoms, age cohort, family history and substance abuse or 
dependence.  Substance use was systematically excluded as the acute cause of the 
incident manic or hypomanic episodes.  The multivariate adjusted models of risk 
estimates used a large number of relevant demographic characteristics, substance 
use/abuse/dependence, individual and family history, and psychiatric comorbidity 
measures to adjust risk estimates and control for potential confounding.  Estimates within 
strata defined by substance abuse or dependence are likely to have less biased cannabis 
use reporting (i.e. demonstrated willingness to report substance use, abuse or 
dependence). 
 
III I. Summary of Findings 
Among those reporting no lifetime major depressive or manic symptoms at baseline self-
reported past-year cannabis use was associated with increased odds of an incident week 
of extremely elevated or irritable mood accompanied by at least two manic episode 
criterion B symptoms (adj. OR 1.69, 95% CI: 1.08-2.65, p=.02) over a three year follow-
up period.  Among adults (ages 26 to 45) >=1 use of cannabis of per week was associated 
with incident manic or hypomanic episodes (adjusted OR 2.52, 95% CI: 1.32-4.80, 
p=.006).  This elevated risk among those aged 26 to 45 remained even when those with 
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lifetime major depressive or manic symptoms at baseline were excluded (adj. OR 2.82, 
95% CI: 1.12 – 7.07, p=.03).  Risk for DSM-IV manic or hypomanic episodes among 
those aged 26 to 45 using cannabis in the past year is concentrated in those with a 
baseline history of a substance use disorder (adj. OR 2.00, 95% CI: 1.10-3.66, p=.02) 
compared to those with no such histories (adj. OR 1.87, 95% CI: 0.49-7.21, p=.36).  
Among those endorsing no major depressive symptoms, substance abuse/dependence or 
anti-social traits in their first degree relatives past year cannabis use is associated with 
increased risk for incident bipolar spectrum disorders (adjusted OR 2.27, 95% CI: 1.01-
5.10, p=.05) and CIDI recalibrated BD I and II (adjusted OR 5.49, 95% CI: 1.38-21.9, 
p=.02).  
 
III J. Conclusions 
This aim finds evidence supporting the conclusion that self-reported cannabis use is a 
significant risk factor for incident bipolar spectrum outcomes within subpopulations in a 
nationally representative cohort.  Specifically adults (aged 18 to 45) reporting cannabis 
use at a high level (>=1 use/week) experience the greatest increase in risk.  The evidence 
points to the underlying liability of a history of a substance use disorder among those 
aged 26 to 45 as a contributor to this elevated risk.  Equally as important is that the 
evidence supports the conclusion that cannabis use is not a significant risk factor for 
incident bipolar outcome within populations that are at elevated risk for bipolar outcomes 
because of a baseline history of MDE or manic symptoms or family history factors.  In 
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contrast, the evidence suggests those at low innate risk because of family history have 
increased cannabis use risk for bipolar disorder outcomes.   
 
Future research needs to explore what specific characteristics of those with substance use 
disorders drives their increased risk for bipolar spectrum disorders associated with 
cannabis use.  Additionally relevant genetic and environmental factors that increase risk 
for bipolar spectrum disorders need to be identified in population representative samples.  
Improved measures of the underlying risk for bipolar spectrum disorders will improve the 
identification of those most at risk for bipolar spectrum disorders as the result of cannabis 
exposure. 
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Chapter IV: 
IV A. Introduction 
A major limitation of the Aim 2 analysis was the low reported prevalence of cannabis use 
in the NESARC.  The National Institute on Drug Abuse (NIDA) Monitoring the Future 
report97 and the 2002 National Survey on Drug Use and Health (NSDUH)54 both point to 
considerable higher cannabis use rates then seen in the NESARC for the year 2001 to 
2002.  Both NIDA’s Monitoring the Future and the NSDUH’s main purpose was the 
collection of substance use information.  The NESARC’s main focus was on alcohol and 
related conditions which included the assessment of a wide range of psychiatric 
comorbidities.  The National Comorbidity Survey Replication (NCS-R) also examined a 
wide range of psychiatric comorbidities in a similar manner and during the same time 
period as the NESARC.59  The reported lifetime use of cannabis among adults (aged 
>=18) was very similar between the NCS-R  at 42.7 % (SE 1.0)99 and the NSDUH  at 
42.8 % (41.9 - 43.7).54 
 
The NCS-R represents a very similar population to that of the NESARC.  The reported 
cannabis use prevalence estimates of the NCS-R are in keeping with other estimates that 
employed anonymous reporting.  These features make the NCS-R a good population to 
make external estimates of cannabis use probabilities within the NESARC.  Using 
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identical measures from both surveys predicted probabilities (i.e. propensity scores) of 
ever using cannabis, use within the past year and high use in the past year (>=1 use/week) 
can be estimated in the NESARC using effect estimates from the NCS-R. The NCS-R 
will function as the external standard.  These predicted probabilities could be used as 
proxies for NCS-R-like exposures within the NESARC.  The use of externally estimated 
exposures will serve as a vehicle to conduct a sensitivity analysis. This sensitivity 
analysis will address the question of how would cannabis use risk estimates might differ 
in the NESARC if cannabis use reporting conformed more closely to our hypothetically 
un-suppressed NCS-R use reports. 
 
IV B. Sensitivity Analysis Methods 
IV B. 1 The surveys sample populations 
The NESARC and the NCS-R represent very similar populations but as their sampling 
frames differed in some respects, differences between the two samples exist.  As 
previously described the main differences between the two surveys is that the sampling 
frame for the NESARC included all 50 states and group quarters such as boarding 
houses, dormitories and shelters where as the NCS-R sampling frame included the lower 
48 states and did not include group quarters.  In the NCS-R students living in dormitories 
from a family in a sampled household were eligible to be sampled.   To assess the 
demographic differences between the two surveys standardized differences in the 
prevalence of individual characteristics were determined.  Cohen’s d is a measure of 
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effect size and is defined as the difference between two means divided by their pooled 
standard deviation.100  Standardized mean differences between the surveys demographic 
characteristics are reported as one hundred times Cohen’s d.  Cohen’s d is a measure of 
effect size between two independent means with increasing absolute values representing 
increasing effect sizes.  A rule of thumb for interpreting the standardized mean 
differences defined here is that absolute values of about 20 represent small effect sizes, 
50 medium effect sizes and 80 large effect sizes.101  The pooled standard deviations were 
calculated by concatenating the two datasets while retaining the data structure (primary 
sampling units, strata) of the individual surveys.  The pooled standard deviations 
represent simple random sample estimates based on the total number of observations of 
both surveys that has taken the design of both surveys into account. 
 
IV B. 2 Exposure Measures 
In the NCS-R cannabis use was assessed in part 2 or the long form of the survey.59  Part 2 
respondents were asked about past 30-day, past year and lifetime substance use, including 
cannabis use.  Part 2 respondents to the NCS-R were weighted to be representative of the 
household population of the 48 contiguous US states.  Reports of ever using cannabis, <1 
use/week in the past year, and >=1 use/week in the past year were dichotomously coded 
(1= reported use, 0=not reported).  These same measures are also found in the NESARC 
and were coded accordingly. 
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IV B. 3 Demographic Measures 
Demographic measures in the two surveys were assessed in very similar ways and 
captured identical traits.  The following demographic measures were found and coded in 
the same manner in both survey data sets: gender (male=1, female=0), age cohort (1= 18 
to 25, 2=26 to 35, 3=36 to 45, and 4 =46 and older), race/ethnicity (white=1, black=2, 
Hispanic or Latino=3, and Other =4), Household income ($) quartiles (1= <=23000, 2= 
23000 to <= 47000, 3= 47001 to <=80500, 4= >=80500), education status (1= < high 
school, 2=high school or GED, 3= some college or an Associate Degree, 4= >= 
Bachelor’s Degree), census region (1= Northwest, 2= Midwest, 3= South, 4= West), 
marital status (1=married or living with someone as if married, 2= divorced or separated 
or widowed, 3= never married), and native birth status (1=native born, 0= not native 
born). 
 
IV B. 4 Analytical Approach 
Three separate models were constructed using the NCS-R data.  These models are 
propensity score models using external data.102  All the demographic variables listed 
above were used as predictive variables in three models of 1) ever using cannabis, 2) past 
12 month use and 3) >=1 use/week in the past 12 months.  The propensity score models 
only included independent variables that were nearly identically assessed and captured 
the same trait between the two surveys.  Enough differences existed between how the two 
surveys accessed other substance use and applied DSM-IV criteria for substance use and 
non-substance use disorders to preclude the use of these measures in the propensity 
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models.  Therefore the independent variables used in the cannabis use propensity score 
models were restricted to the demographic variables listed above.  The propensity score 
models discrimination characteristics within the NCS-R were assessed by the area under 
the receiver operator characteristic curve (AUC).    
 
Coefficients from each NCS-R cannabis use model were used to generate predicted 
probabilities within the NESARC dataset (predicted probabilities=1/[1 + e^(β0, NCS-R + 
male*βmale,NCS-R + …+ native born*βnative born,NCS-R)]).  Effect estimates from the NCS-R 
were used, in other words, to generate a propensity score within the NESARC.  The mean 
predicted probabilities of the three exposure models within the NESARC represent an 
estimation of the prevalence of the given exposure (i.e. a perfectly predicted exposure 
would have probabilities of 1 and 0, the mean of which would be its prevalence).  The 
mean predicted values from the NESARC were examined for their consistency with 
prevalence estimates from the NCS-R taking into consideration meaningful differences 
that may exist between the two samples.  
 
IV B. 5 Categorizing Predicted Exposures 
Risk estimates of continuous predictors of exposure (i.e. propensity score) can be hard to 
interpret and compare to risk estimates from dichotomous or categorical exposures (i.e. 
our reported use exposures).  To facilitate comparison of the predicted exposures and the 
reported exposures cut points were establish to classify the predicted probabilities into 
categorical variables.  After inspection and satisfaction that the mean predicted 
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probabilities of the three exposure prediction models were reasonable, cut points at the 
mean predicted probability (i.e. the estimated prevalence) were imposed.  In other words, 
for a mean predicted probability of say .40, the highest 40% of the predicted probability 
would be code 1 and the lowest 60% coded as 0.  The high use level (>= 1 use/week in 
the past 12 months) was defined as: the highest predicted probability from the high use 
propensity model while maintaining the total prevalence at the mean predicted 
probability (i.e. the cut point) of the high use propensity score model.  The past year use 
level was defined as including: respondents already classified as high use (in past year) or 
respondents with the highest predicted probability from the past year use model while 
maintaining the total prevalence at the mean predicted probability of the past year 
cannabis use propensity model.  Similarly the ever using cannabis level was defined as 
including: respondents already classified in the past year group or respondents with the 
highest predicted probability from the ever use model while maintaining the total 
prevalence at the mean predicted probability of the ever used cannabis propensity model.  
These three indicators were used to define the four level categorized predicted probability 
variable: 1) those with no use, 2) >= 1 use/week in the past 12 months, 3) <1 use/week 
past 12 month and 4) prior to past 12 month use.  Also separate dichotomous indicators 
for predicted proximal and predicted distal cannabis use were also specified.   
 
IV B. 6 Assessment of propensity score based classified exposure variable 
Standardized mean differences between NCS-R cannabis use prevalence estimates and 
the NESARC reported and predicted cannabis use estimates will be reported.  To assess 
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how well the above describes classification schemas improved classification within our 
domain of interest, standardized mean differences between the NCS-R and the NESARC 
for reported and predicted cannabis use by bipolar spectrum disorder status (cross-
sectional prevalence of DSM-IV manic or hypomanic episodes from wave 1 of the 
NESARC and the NCS-R) will be compared.  An improvement in the balance between 
the NCS-R and the NESARC on the cross-sectional relationship between cannabis use 
status and bipolar outcomes will provide a measure of support for the validity of the 
exposure classifications. 
 
IV B. 7 Sensitivity Analysis 
Reported cannabis use and predicted cannabis use risk estimates will be compared among 
groups with significant effect estimates reported in Chapter 3 (i.e. incident manic 
symptoms, among adults age 26 to 45, by family history status and by substance use 
disorder status).  These analyses will provide evidence as to how sensitive risk estimates 
in the NESARC are to improved hypothetically less biased ‘NCS-R-like’ reporting.  
Continuous predicted probabilities or their log transformed values will also be included in 
multivariate models of incident bipolar spectrum outcomes in the NESARC.  These 
analyses will provide evidence as to whether cannabis use propensity is associated with 
risk for bipolar spectrum outcomes. 
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IV C. Results 
Table 4.1 shows the balance of the means of the demographic characteristics between the 
two surveys.  There is good balance between the two surveys with two notable 
exceptions, the NESARC has a lower proportion of those in the highest income group 
and also has fewer respondents reporting being native born.  The prediction models have 
fair to good discrimination characteristic (Table 4.2).  Table 4.3 shows the mean 
predicted probabilities of the three models.  The models predict slightly lower prevalence 
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estimates (i.e. mean predicted probability) across all three models as compared to the 
NCS-R.  The performance of the prediction models and the classification schema are 
presented in Table 4.4.  The standardized differences of the reported use groups in the 
cohort as a whole were all >20 with the exception of the past year high use group (17.2).  
In the cohort as a whole there are small differences in the means between the reported 
and predicted classification groups.  Within groups defined by cross-sectional bipolar 
spectrum disorder status the reclassification schema improved the concordance (i.e. 
lowered standardized differences) between the NCS-R and the NESARC for the 
predicted exposure groups.  Reported use is more strongly associated with bipolar 
outcome in the NESARC than in the NCS-R (lower standardized differences), 
particularly for the high use group. 
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IV C. 1 Risk Estimates with Predicted Exposure Groups 
Tables 4.5 to 4.7 report the predicted cannabis use risk estimates in comparison with the 
reported estimates.  Of the significant risk estimates for reported cannabis use in Chapter 
3, none are found to be significant for categorized predicted use.  Only for incident manic 
symptoms outcomes did predicted cannabis use risk approaches significance (adjusted 
OR 1.54, 95% CI: 0.99-2.38, p=.054).   
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IV C. 2 Risk Estimates with Cannabis Use Propensities 
Table 4.8 shows the odds of bipolar spectrum outcomes per unit of predicted probability 
for the three predicted exposures.  Propensity for ever using cannabis was not 
significantly associated with bipolar spectrum outcomes, a unit change in the log 
transformed continuous probability of past year use and >=1 use/week in the past year 
were significantly associated with bipolar spectrum outcomes among adults aged 18 to 
45.  Table 4.9 reports risk for incident bipolar spectrum outcomes for individual cannabis 
use propensities by family history strata.  Cannabis use propensities for past year and 
high use in the past year are both significantly associated with bipolar spectrum outcomes  
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for those in the no reported family history group.  Cannabis use propensities are not 
associated with incident outcomes among those in the lowest or highest median family 
history groups.  Among those with no reported substance use disorders at baseline, 
propensities for past year and high use in the past year are both significantly associated 
with bipolar spectrum outcomes (Table 4.10).  A significant effect estimate was also 
found for past year cannabis use propensity for those reporting a lifetime substance use 
disorder at wave one. 
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IV C. Comments 
NCS-R represents a good choice for an external study to generate a propensity score 
within the NESARC.103  The measures used in the propensity models were the same in 
both studies and the validation measure, bipolar spectrum disorders were assessed in a 
similar manner (within the context of some differences seen in Aim 1).  The differences 
between the study populations reasonably account for the differences in the prevalence of 
exposure reported in the NCS-R and those predicted in the NESARC.  The greater 
proportion of native born and higher income respondents in the NCS-R (Table 4.1), both 
of whom report ever using cannabis at proportionally higher rates, likely accounts for the 
lower mean predicted probabilities (prevalence estimates) of cannabis use estimated in 
the NESARC.   The disproportionately higher reporting of cannabis use (lower relative 
standardized mean differences, Table 4.4) among those with bipolar spectrum disorders 
at wave 1 in the NESARC points to differential reporting of cannabis use by cross-
sectional bipolar spectrum status as compared to the NCS-R external standard. 
 
The improvement in the proportions of the predicted exposure group, compared to 
reported use, across bipolar spectrum status provides support for these propensity score 
derived exposure measures as being reasonable proxies for ‘NCS-R-like’ exposures, the 
goal of the re-classification schemas (Table 4.4).  The propensity score derived exposure 
measures may be reasonable proxies for un-suppressed cannabis use reporting, it still is 
however an undesired substitute for a well measured exposure with little 
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misclassification.  Absent a well measured exposure with little misclassification 
propensity score derived measures of exposure represent a reasonable alternative. 
 
The propensity scores as continuous measures point to any past year cannabis use and 
>=1 use/week of cannabis in the past year as significant risk factors for incident manic 
and/or hypomanic episodes among those 18 to 45 years of age. Risk associated with 
propensity for cannabis use in the past year or high use in the past year is concentrated in 
those at relatively low risk for incident manic outcomes:  those with no reported family 
history and those with no history of substance use disorders.  The inefficiencies incurred 
by introducing cut points for the categorized predicted exposures may explain their lack 
of replicating this result.   Also, inefficiencies in the propensity model themselves may 
have also contributed (i.e. no substance use/abuse/dependence or family history 
measures) to the result that propensity for high cannabis use was not a significant risk in 
the substance use disorder strata (Table 4.10).  The significant increased risk for bipolar 
spectrum disorders seen for past year cannabis use propensities within relatively low risk 
groups suggests the possibility that those with lower innate risk (i.e. genetic load) may be 
more susceptible to cannabis exposure and/or said risk maybe more efficiently detected.   
 
IV D. Limitations 
The propensity score models only rely on demographic variables and their discrimination 
characteristics were not ideal.  Other non-illicit substance use measures such as tobacco 
and alcohol use/abuse differed between the surveys preventing their inclusion in the 
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predictive models of cannabis exposure.  The validation standard, NCS-R bipolar 
spectrum disorders, was not assessed in the exact same manner in both surveys as 
described in Aim 1.  The external data set was only cross-sectional preventing validation 
of our exposure and outcome in the longitudinal context.  Correction for lost to follow-up 
is incorporated into wave 2 weights and as such can not be directly assessed in the 
context of out particular exposure and outcome.  As in Aim 2 characteristics of the family 
history score may have influenced risk estimates in the no family history and lowest 
median family strata.   
 
IV E. Summary of Findings 
No risk estimates for categorized predicted exposures were found to be significant among 
estimates that were significant for reported exposures.  However, among adults 18 to 45 
years of age with no manic or major depressive symptoms at baseline, past year cannabis 
use propensity (as a log transformed continuous measure) was associated with incident 
manic or hypomanic episodes (adj. OR 1.49, 95% CI: 1.10-2.03, p=.01).  Elevated risk 
for high cannabis use propensity (>=1 use/week in the past year) was also found in this 
same group (adj. OR 1.33, 95% CI: 1.03-1.72, p=.03).  Among those with no reported 
history of depression, alcohol or substance abuse/dependence, or anti-social traits among 
their first-degree relatives, propensity for past year cannabis use (adj. OR 1.61, 95% CI: 
1.11-2.32, p=.01) and propensity for >=1 use/week in the past year (adj. OR 1.38, 95% 
CI: 1.03-1.85, p=.03) was associated incident manic or hypomanic episodes.  Among 
those without a substance use disorder history at baseline, propensity for past year 
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cannabis use (adj. OR 1.63, 95% CI: 1.33-1.55, p<.001) and propensity for >=1 use/week 
in the past year (adj. OR 1.54, 95% CI: 1.26-1.88, p<.001) were associated incident 
manic or hypomanic episodes.  Among those with a substance use disorder history at 
baseline, propensity for past year cannabis use (adj. OR 1.26, 95% CI: 1.03-1.56, p= .03) 
was associated incident manic or hypomanic episodes. 
 
IV F. Conclusions 
A sensitivity analysis was conducted that compared predicted cannabis exposure risk 
estimates for incident bipolar spectrum outcomes to risk estimates based on reported 
cannabis exposures.  Evidence from categorized predicted exposures does not support a 
significant association (p<.05) between cannabis use and bipolar outcomes.  However, 
evidence from the continuous propensity measures is largely in accord with the results 
from Aim 2. Specifically the evidence supports the conclusion that any or high cannabis 
use levels in the past year predicts bipolar spectrum disorders in adults age 18 to 45, 
those with no reported family history and those with a substance use history.  The 
sensitivity analysis provided additional evidence supporting the conclusion that those at 
low inherent risk for bipolar disorders, namely those without a substance use history, are 
at increased risk from cannabis exposure.  Risk estimates from cannabis use propensities 
based on an external data source largely support risk estimate based on reported use.  
Future research in this area will benefit from better exposure measurement. 
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Chapter V: 
V A. Implications 
V A.  1 Public use data sets: Caution 
Evidence from the first aim of this dissertation supports the use of caution among 
researcher using public use data sets.  Such caution should be applied even more 
strenuously when such public use data set do not publish algorithms for their constructed 
variables (e.g. diagnoses) as is true for the NESARC.  The publication of such algorithms 
however does not guarantee that the operationalization of diagnostic criteria is ideal, as 
was demonstrated with manic and hypomanic episodes in the NCS-R.  The current 
version of the CIDI retains the features described in Aim 1.104  The latest version of the 
AUDADIS (AUDADIS-V)105 still does not  explicitly assesses anhedonia and depressed 
mood within the same mood episode, it dose however ask additional screening questions 
to those endorsing as few as four major depressive episode symptoms (including 
anhedonia or depressed mood) before they are skipped out of the major depressive 
episode section. 
V A. 2 Practical considerations from Aim 1 
Practical considerations result from the findings of Aim1.  Studies with a focus on major 
depressive episode should consider the implications of symptom assessment when using 
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NESARC data.  The ‘un-assessed’ MDE group of Aim 1 endorsed a total of only five 
MDE symptoms of which only four are known to be within the same episode.  One might 
be tempted to infer that this group is ‘less severe’ than those with more symptoms 
mitigating their misclassification.  However nearly a quarter of this ‘un-assessed’ group 
(22.3%, 95% CI: 18.9-25.7) endorsed having thoughts of death or suicide demonstrating 
that this group misclassification should not be ignored.  The finding that very few 
lifetime major depressive episodes are excluded for bereavement meeting DSM-IV 
criteria suggests that bereavement related major depressive episodes are not qualitatively 
different from non-bereavement related episodes. This result is evidence in support of the 
decision to eliminate the bereavement exclusion in the DSM-V. 106, 107  
 
The impact of the assessment of impairment in manic/hypomanic episodes within the 
AUDADIS should also be considered when using NESARC data.  Estimates of Bipolar I 
prevalence using all of the impairment indices of the AUDADIS are clearly inflated 
(Table 2.2) compared to a CIDI-type assessment.  The shifting of manic episode cases to 
hypomanic episodes was not a major issue in this dissertation’s analyses of cannabis use 
risk as bipolar spectrum outcomes (manic or hypomanic episodes) were assessed.  It 
should be recognized however that the assessment of impairment is difficult and those 
not endorsing impairment may lack insight.  Making the distinction between a manic 
episode and a hypomanic episode based on self-reports is inherently an imprecise 
enterprise.  For instance about a fifth (20.6% 95% CI: 15.1-26.1) of those meeting manic 
episode criteria in the AUDADIS approach but not in the AUDADIS/CIDI approach 
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(n=295) endorsed six or more symptoms suggesting they may indeed have been impaired 
in spite of their failure to endorse any of the impairment measures.   
 
V A. 3 Implications for CIDI 
The CIDI operationalization of manic episode impairment criterion would benefit from 
assessing hospitalization or mental health professional contact before respondents are 
skipped out.  Also the CIDI would be also be improved by flagging those endorsing 
psychotic/delusional features and collecting complete criterion information on them.  
Psychosis is a difficult trait to assess in a population based self-reported symptom 
setting108, 109 it may however be less difficult to attain accurate self-reports of elevated or 
irritable mood related hospitalization or mental health professional contact.  These 
changes are reasonable to consider as the CIDI transitions from assessing diagnoses 
according to the DSM-IV to those meeting DSM-V criteria. 
 
Among those 18 to 45 years of age propensity for cannabis use with in the past year and 
propensity for greater than one use of cannabis per week in the past year are associated 
with incident manic or hypomanic episodes (Table 4.8).  These results are all the more 
compelling in that all those reporting a week or more of extremely elevated or irritable 
mood or two weeks or more of anhedonia or depressed mood were excluded from the 
analyses.  Risk from cannabis is concentrated in those aged 26 to 45 with histories of 
substance use disorders.   This result supports a hypothesis that cannabis may precipitate 
the onset of a bipolar spectrum disorder in those with a demonstrated liability for 
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substance abuse or dependence.48, 49  Future research in this area exploring factors that 
may further explain this increased risk is needed (i.e. kind, duration and severity of 
substance use disorders).  The result that those aged 18 to 45 reporting no family history 
suggests that either: 1) those at relatively low risk may be more susceptible to cannabis 
exposure and/or 2) that the detection of increased risk within a low risk population maybe 
more efficient.   Future population based research also needs to better identify those with 
genetic risk for bipolar disorders and substance use disorders in order to better identify 
those most at risk from cannabis exposure. 
 
The results of Aim 2 reported in Chapter 3 need to be considered in the light of the 
evidence of differential reporting of cannabis use.  In Chapter 4 it was found that 
NESARC respondents on the bipolar spectrum at baseline reported cannabis use less 
differently from the external standard (lower standardized mean differences) then those 
not on the bipolar spectrum (Table 4.4).  This finding points to those with more 
psychiatric involvement being more likely to report cannabis use.  This is consistent with 
the observation of Grucza et al54 that the prevalence of substance use disorders including 
cannabis use disorders in the NESARC did not differ from the NSDUH whereas reported 
cannabis use in the NESARC was half that of the NSDUH (i.e. use not to the level of a 
substance use disorder was less likely to be reported).  If one assumes that cannabis use 
reporting in the NCS-R is un-biased, the improved cross-sectional association with 
bipolar spectrum disorders of predicted use compared to reported use serves to provide a 
measure of validation for the propensity models as reasonable proxies for un-biased 
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cannabis use reporting.  The risk estimates based on the propensity scores represent the 
best metric to assess whether cannabis use is a significant risk factor for bipolar spectrum 
disorders absent well measured exposures; as the propensity scores are not burdened with 
the added inefficiencies of cut-points that the categorized predicted exposure introduces.  
The assumption that cannabis use reporting in the NCS-R has low misclassification 
however may not be a reasonable one.  The validity of risk estimates in this dissertation 
may be undermined by under-reporting of both cannabis exposure and other illicit 
substances that may confound the relationship between cannabis and bipolar disorder.  
Reasonable efforts were made to address cannabis under-reporting though the use of 
external cannabis propensity scores but potential uncontrolled confounding introduced by 
other illicit substance use under-reporting remains. 
 
Future population based research on cannabis needs to find approaches to address the 
issue of illicit drug use under-reporting.  It may be that using federal government 
employee should not be the first choice when recruiting those to conduct face-to-face 
interviews.  The true gold standard for cannabis exposure is a biological measure of 
exposure.  However those reluctant to accurately report their cannabis use may be equally 
reluctant to participate in research where biological samples are collected and tested for 
the metabolites of illegal substances.  Future studies should consider the use of 
anonymous reporting approaches such as computerized self-administration and the use of 
Certificates of Confidentiality.  Certificates of Confidentiality allow investigators to 
refuse to disclose information on research participants in any criminal, civil, 
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administrative, legislative, or other proceeding, whether at the local level, state, or federal 
level.110  This may make  participants feel more at ease about disclosing illegal activates 
including the use of illicit substances such as cannabis, knowing that such disclosures are 
unlikely to put them in legal if not social jeopardy.  
 
V B. Conclusion 
Consumers of public use study data need to recognize possible deficiencies that may 
unfortunately be found in these important resources.  In the data sets used in this 
dissertation a considerable proportion of those meeting or with a high likelihood of 
meeting DSM mood disorder criteria are not being identified and/or assessed 
appropriately.  Future survey instruments need to validate that their operationalization of 
diagnostic criteria does not violate criterion structure. 
  
Evidence is found that self-reported or propensity for any or elevated cannabis use in the 
past year is associated with incident manic or hypomanic episodes within sub-populations 
in a nationally representative sample.  Risk from cannabis is concentrated in those aged 
26 to 45 with histories of substance use disorders, a result consistent with observations in 
clinical manic cohorts.  A novel finding of this dissertation is that cannabis use 
propensity risk is also concentrated in those at inherently low risk for incident bipolar 
outcomes via family history characteristics and not having a history of a substance use 
disorder.  This result merits further investigation with improved measures of underlying 
risk.  The use of self-reported cannabis use is a weakness in this dissertation.  Future 
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studies should employ biological measures of exposure, anonymous reporting and/or 
Certificates of Confidentiality to improve measures of cannabis and other illicit substance 
use.  
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Appendix A: Page 1 
 
 
Revised NCSR algorithm for Bipolar Spectrum 
 
We re-calibrated bipolar disorder using our clinical data in the United States and significantly improved the 
concordance of the CIDI and the SCID (validity statistics are attached). To do this we worked with several 
experts in the bipolar field.  They told us that the cidi was over-estimating bipolar I disorder.  Therefore we 
went back to the raw data and looked for patterns in the data to arrive at new, more restrictive definitions of 
bipolar I, II, and created a new variable called bipolar sub-threshold.  We tested these new definitions by 
using the validity statistics to see how well these did in predicting the clinical dx in the clinical sample.  
The best definition was as follows: 
 
WMH CAPI 
Manic Episode(Old Version) – DSM-IV Criteria(DSM_MAN_OLD) 
 
A. Part 1 AND Part 2 
 
Part 1. A distinct period of abnormally and persistently elevated, expansive, or irritable mood. 
 
      SC24 = Yes(1) OR SC25a = Yes(1) 
 
Part 2. A distinct period of abnormally and persistently elevated, expansive, or irritable mood lasting at 
least 1 week(or any duration if hospitalization is necessary).  
 
     (M3b >= 1 week) OR (M3d >= 1 week) OR (M6b >= 1 week) OR (M6d >= 1week) OR  
     (0 < M20 < 998)OR (M22 >= 1 week) OR M48 is Yes(1) 
 
B.   During the mood disturbance, three(or more) of the following symptoms have persisted(four if the 
mood is only irritable) and have been present to a significant degree: 
 
Mood is only irritable: SC25a is Yes(1) and (SC24 is NOT Yes(1)) 
 
1. inflated self-esteem or grandiosity 
 
M7n is Yes(1) OR M7o is Yes(1) 
 
2. decreased need for sleep(e.g., feels rested after only 3 hours of sleep) 
 
M7j is Yes(1) 
 
3. more talkative than usual or pressure to keep talking 
 
M7f is Yes(1) 
 
4. flight of ideas or subjective experience that thoughts are racing 
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M7i is Yes(1) 
 
5. distractibility (i.e., attention too easily drawn to unimportant or irrelevant external stimuli) 
 
M7g is Yes(1) OR M7h is Yes(1) 
 
6. increase in goal-oriented activity(either socially, at work or school, or sexually) or psychomotor 
agitation. 
 
M7a is Yes(1) OR M7b is Yes(1) OR M7c is Yes(1) OR M7e is Yes(1) 
 
7. excessive involvement in pleasurable activities that have a high potential for painful 
consequences(e.g., engaging in unrestrained buying sprees, sexual indiscretions, or foolish business 
investments) 
 
M7k is Yes(1) OR M7l is Yes(1) OR M7m is Yes(1) 
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WMH CAPI 
Manic Episode(Old Version) – DSM-IV Criteria(DSM_MAN_OLD) 
 
C.     The symptoms do not meet criteria for a Mixed Episode  
 
         Not Operationalized 
 
D.     Part 1 OR Part 2 OR Part 3 
 
Part 1. The mood disturbance is sufficiently severe to cause marked impairment in occupational functioning 
or in usual social activities  or relationships with others. 
  
          M9 is (4,5) OR M9a is (1,2) OR (at least 1 of M27a-M2d is between 7 and 10) OR 
          (5 <= M29 < 365) OR M33 is Yes(1) 
 
Part 2. The mood disturbance is sufficiently severe to necessitate hospitalization to prevent harm to self. 
 
          M48 is Yes(1) 
 
Part 3. There are psychotic features 
 
          M7o is Yes(1) 
 
E.   The symptoms are not due to the direct physiological effects of a substance(e.g., a drug of abuse, a 
medication, or other treatment) or a general medical condition (e.g. hyperthyroidism) 
 
         NOT(M10b is Yes(1)) AND M10a is(1,5,8,9) 
 
NOTE: M10b is used as an initial screener only.  All open ended items are reviewed by a clinician to 
determine organic exclusion. 
 
WMH CAPI Bipolar I Old 
 
DSM_MAN_OLD is Yes(1) 
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WMH CAPI 
Hypomanic Episode(Old version) – DSM-IV Criteria(DSM_HYP_OLD) 
 
A.   Part 1 AND Part 2 
 
Part 1. A distinct period of abnormally and persistently elevated, expansive, or irritable mood. 
 
      SC24 is Yes(1) OR SC25a is Yes(1) 
 
Part 2. A distinct period of abnormally and persistently elevated, expansive, or irritable mood lasting at 
least 4 days, that is clearly different from the usual nondepressed mood.  
 
     SC24 is Yes(1) OR (M3b >= 4 days) OR (M3d >= 4 days) OR (M6b >= 4 days) OR (M6d >= 4 days) 
OR 
     (0 < M20 < 998) OR  (M22 >= 4 days) 
 
B.  During the mood disturbance, three(or more) of the following symptoms have persisted(four if the 
mood is only irritable) and have been present to a significant degree: 
 
Mood is only irritable: SC25a is Yes(1) and (SC24 is NOT Yes(1)) 
 
1. inflated self-esteem or grandiosity 
 
M7n is Yes(1) OR M7o is Yes(1) 
 
2. decreased need for sleep(e.g., feels rested after only 3 hours of sleep) 
 
M7j is Yes(1) 
 
3. more talkative than usual or pressure to keep talking 
 
M7f is Yes(1) 
 
4. flight of ideas or subjective experience that thoughts are racing 
 
M7i is Yes(1) 
 
5. distractibility (i.e., attention too easily drawn to unimportant or irrelevant external stimuli) 
 
M7g is Yes(1) OR M7h is Yes(1) 
 
6. increase in goal-oriented activity(either socially, at work or school, or sexually) or psychomotor 
agitation. 
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M7a is Yes(1) OR M7b is Yes(1) OR M7c is Yes(1) OR M7e is Yes(1) 
 
7. excessive involvement in pleasurable activities that have a high potential for painful 
consequences(e.g., engaging in unrestrained buying sprees, sexual indiscretions, or foolish business 
investments) 
 
M7k is Yes(1) OR M7l is Yes(1) OR M7m is Yes(1) 
 
C.  The episode is associated with an unequivocal change in functioning that is uncharacteristic of the 
person when not symptomatic.  
 
M9 is (3,4,5) OR M9a is (1,2,3) OR (at least 1 of M27a-M2d is between 4 and 10) OR  
(2 <= M29 <= 365) OR M33 is Yes(1).  
 
D.  The disturbance in mood and the change in functioning are observable by others. 
 
    Not Operationalized  
 
145 
Appendix A: Page 4 
WMH CAPI 
Hypomanic Episode(Old version) – DSM-IV Criteria(DSM_HYP_OLD) 
 
E.      Part 1 AND Part 2 AND Part 3. 
 
Note: By strict DSM criteria, those people who meet all criteria for mania but have a duration of  4 to 6 
days without hospitalization are excluded from a diagnosis of hypomania.  (See mania criterion A,D and 
hypomania criterion E).  We have defined these people as meeting hypomania. This is implemented by 
suppressing Criterion E for those with a duration of 4 to 6 days and without hospitalization.       
 
Part 1. The mood disturbance is not severe enough to cause marked impairment in occupational functioning 
or in usual social activities  or relationships with others. 
 
       NOT (M9 is (4,5) OR M9a is (1,2) OR (at least 1 of M27a-M27d is between 7 and 10) OR 
                (5 <= M29 < 365) OR M33 is Yes(1)) 
 
Part 2. The mood disturbance is not severe enough to necessitate hospitalization to prevent harm to self. 
 
       M48 is No(5) 
 
Part 3. There are no psychotic features 
 
       M7o is No(5) 
 
F.  The symptoms are not due to the direct physiological effects of a substance(e.g., a drug of abuse, a 
medication, or other treatment) or a general medical condition (e.g. hyperthyroidism) 
 
      NOT(M10b is Yes(1) AND M10a is(1,5,8,9)) 
 
NOTE: M10b is used as an initial screener only.  All open ended items are reviewed by a clinician to 
determine organic exclusion. 
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WMH CAPI Bipolar II Old 
 
A.  Presence (or history) of one or more Major Depressive Episodes         
 
      dsm_mde is Yes(1)  
 
B. Presence (or history) of at least one Hypomanic Episode                           
 
      dsm_hyp_old is Yes(1)  
 
C. There has never been a Manic Episode or Mixed Episode  
 
     dsm_man_old is NOT Yes(1) 
  
E. The symptoms cause clinically significant distress or impairment in social,         
   occupational, or other important areas of functioning.                              
 
     M9 is (3,4,5) OR M9a is (1,2,3) OR (at least 1 of M27a-M2d is between 4 and 10) OR  
     (5 <= M29 <= 365) OR M33 is Yes(1)  
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WMH CAPI  
Recalibrated Bipolar I/II/Sub, Mania, Hypomania, Sub-Hypomania 
 
Bipolar I 
 
   dsm_man_old is Yes (1) AND at least 6 symptoms in the M7 series(DSM_MAN_OLD Criteria B1-B7) 
AND at least two of the following symptoms: M7b, M7c, M7k, M7l, M7o is 1(yes) 
 
Bipolar II  
 
NOT Bipolar I AND 
 
(Bipolar I Old is Yes (1) AND dsm_mde = 1 AND M1 = 1 AND M7i = 1)    
Note: These are the people who meet criteria for our old bipolar I definition (mania) but no longer meet 
criteria  with the new definition, and have a major depressive episode and euphoria and racing thoughts  
 
 OR  
(Bipolar II Old is Yes(1) AND 
  (M3b >= 14 days OR M3d >= 14 days ORM6b >= 14 days OR M6d >= 14 days or M20>= 14 days OR 
M22 >=14 days) AND 
   at least 2 of the following symptoms (M7b,M7c,M7k,M7l,M7o) )  
Note: This is our old definition of bipolar II (in italicized text) tightened up to include a duration of at least 
14 days and  at least 2 of the “super” symptoms in terms of concordance  
 
Bipolar Sub 
Note:  anyone left with old mania/hypomania who did not meet criteria for bipolar I and bipolar II above 
 
Not Bipolar I or Bipolar II as defined above AND (dsm_man_old is Yes(1) OR dsm_hyp_old is Yes(1)) 
 
Mania (dsm_man) 
 
   Bipolar I is Yes(1) 
 
Hypomania (dsm_hyp) 
 
   Bipolar II is Yes(1) OR (Bipolar Sub is Yes(1) AND dsm_man_old is Yes(1)) 
 
Sub-Hypomania (dsm_hypsub) 
 
   Bipolar Sub is Yes(1) AND (Bipolar II Old is Yes(1) OR dsm_hyp_old is Yes(1)) 
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Appendix D: Page 1 
WMH CAPI 
DSM-IV Major Depressive Episode 
 
A.   Five(or more) of the following symptoms have been present during the same 2-week period and 
represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or 
(2) loss of interest or pleasure.  Note:  DSM-IV states that children and adolescents may be “irritable 
rather than sad”.  This is not operationalized when examining adults who report symptoms from 
childhood. 
 
 Part 1 AND Part 2. 
 
Part 1. Symptoms have been present during the same 2 week period and at least one of the symptoms is 
either(1) depressed mood or (2) loss of interest or pleasure. 
                     
         (D22b >= 2 weeks OR D22d >= 2 weeks OR D39 >= 2 weeks)  AND 
         (D24a is Yes(1) OR D24b is Yes(1) OR D24c is Yes(1) OR D24d is Yes(1) OR D24e is Yes(1) OR 
D24f is Yes(1) 
 
 
Part 2. At least five of the following symptoms must be present and represent a change from previous 
functioning: 
 
Note: “change from previous functioning” is implicit in the item corresponding to each symptom (e.g. 
“more than usual”, “less than usual”). 
 
         1. depressed mood most of the day, nearly every day, as indicated by either subjective report(e.g., 
feels sad or empty) or observation made by others. 
 
          D24a is Yes(1) OR D24b is Yes(1) OR D24c is Yes(1) OR D24d is Yes(1) 
 
         2. markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly 
every day(as indicated by either subjective account or observation made by others) 
 
 D24e is Yes(1) OR D24f is Yes(1)  
 
        3. significant weight loss when not dieting or weight gain (e.g., a change of more than 5% of body 
weight in a month), or decrease or increase in appetite nearly every day. 
 
D26a is Yes(1) OR (D26f  >= 10 lbs) OR D26b is Yes(1) OR (D26d >= 10 lbs) 
 
        4. insomnia or hypersomnia nearly every day. 
 
D26g is Yes(1) OR D26h is Yes(1) 
 
        5. psychomotor agitation or retardation nearly every day(observable by others, not merely subjective 
feelings of restlessness or being slowed down). 
 
D26m is Yes(1) OR D26o is Yes(1) 
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        6. fatigue or loss of energy nearly every day. 
 
D26j is Yes(1) 
 
        7. feelings of worthlessness or excessive or inappropriate guilt(which may be delusional) nearly every 
day(not merely self-reproach or guilt about being sick)  
 
D26v is Yes(1) 
 
        8.  diminished ability to think or concentrate, or indecisiveness, nearly every day(either by subjective 
account or as observed by others) 
 
D26p is Yes(1) OR D26r is Yes(1) OR D26s is Yes(1) 
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WMH CAPI 
DSM-IV Major Depressive Episode 
 
A.  Part 2. 
 
         9. recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific 
plan, or a suicide attempt or a specific plan for committing suicide. 
 
D26aa is Yes(1) OR D26bb is Yes(1) OR D26cc is Yes(1) OR D26dd is Yes(1) OR D26ee is Yes(1) 
 
B.    The symptoms do not meet criteria for a Mixed Episode 
 
Not operationalized. 
 
C.   Part 1 OR Part 2. 
 
Part 1. The symptoms cause clinically significant distress. 
 
           D17 is (2,3,4) OR D18 is (1,2) OR D19 is (1,2,3) OR D24b is Yes(1) 
 
Part 2. The symptoms cause clinically significant impairment in social, occupational, or other important 
areas of functioning. 
 
           D28 is (3,4,5) OR D28a is (1,2,3) OR   (At least 1 value of D66a-D66d is between 4 and 10)  
 
D.  The symptoms are not due to the direct physiological effects of a substance (e.g., a drug of abuse, a 
medication), or are not due to a general medical condition. NOTE: D29b is used as an initial screener 
only.  All open ended items are reviewed by a clinician to determine organic exclusion. 
 
            NOT(D29b is Yes(1)) AND D29a is (1,5,8,9) 
 
E.    Part 1 OR Part 2 OR Part 3 
 
Part 1. The symptoms are not better accounted for by Bereavement.   
  Not operationalized. 
Part 2. If the symptoms are associated with bereavement, they persist for longer than two months 
         Not operationalized 
Part 3.  If the symptoms are associated with bereavement, they are characterized by (a) marked functional 
impairment, (b) morbid preoccupation with worthlessness, (c) suicidal ideation, (d) psychotic symptoms, or 
(e) psychomotor retardation. At least one of a-e must be present. 
          Not operationalized 
NOTE: D23 was deleted from the instrument therefore the bereavement criteria could not be 
operationalized. 
 
